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INTRODUCTION
1Gestational trophoblastic disease (GTD) comprises a spectrum of
disorders characterized by an abnormal proliferation of trophoblastic tissue
after a normal or abnormal fertilization with varying propensity to
spontaneously regress, locally invade and metastasize.
 Hydatidiform mole is the most common form of GTD, and can be
subdivided into
? Complete mole (CM)
? Partial mole (PM)
 The malignant forms are
? Invasive mole
? Choriocarcinoma(CC)
? Placental site trophoblastic tumor(PSTT)
? Epithelioid   trophoblastic tumor (ETT)
Hydatidiform mole and invasive mole are villous forms of GTD and
choriocarcinoma and PSTT are non villous forms of GTD.
There are wide variations in the incidence and epidemiological factors
worldwide and there are changing trends in clinical presentation and
management. This implicates the need for region specific studies of GTD.
2Gestational trophoblastic neoplasms are one of the most curable of all
solid tumors with cure rates more than 90% with fertility retention even in the
presence of widespread metastasis.
This success can be explained by the use of serum ? hCG as a
biomarker for follow up and development of effective chemotherapy
regimens.
In UK all patients are included in a national register with a central
pathologic review. As there are no registries for trophoblastic disease
available in India, the actual incidence of GTD is not known.
It is important to analyze the natural history, follow up, treatment and
outcome of this unique condition.  This will help making decisions and
optimizing management and preventing treatment failure.
OVERVIEW OF
GESTATIONAL
TROPHOBLASTIC DISEASE
3Hippocrates was probably the first to describe gestational trophoblastic
disease around 400 BC in his description of dropsy of the uterus.
In 1276, Margret, Countess of Henneberg delivered some 365 children,
baptized in two basins, boys being christened John and girls Elizabeth.
 Marchand first associated hydatidiform mole with pregnancy in 1895.
The etymology is derived from hydatisia ("a drop of water"), referring to the
watery contents of the cysts, and mole (“millstone”), meaning false
conception.
Healthy trophoblastic tissue aggressively invades the endometrium and
develops a rich uterine vasculature, generating an intimate connection
between the fetus and the mother known as the placenta.
Trophoblasts (from Greek trephein: to feed, and blastos: germinator)
are cells forming the outer layer of a blastocyst, which provide nutrients to
the embryo and develop into a large part of the placenta. Trophoblasts are
specialised cells of the placenta that play an important role in embryo
implantation and interaction with the decidualised maternal uterus. The
trophoblast proliferates and differentiates into 2 cell layers at approximately 6
days after fertilization.
4Layer Location Description
cytotrophoblast inner layer
Single celled, inner layer of the
trophoblast.
syncytiotrophoblast outer layer
Thick layer that lacks cell boundaries and
grows into the endometrial stroma. It
secretes  ? hCG in order to maintain
progesterone secretion and sustain a
pregnancy.
intermediate
trophoblast (IT)
implantation site,
chorion  &  villi
(dependent on
subtype)
anchor placenta (implantation site IT),
unknown (chorionic & villus IT)
Cytotrophoblast is considered to be the trophoblastic stem cell; it
differentiates into the other forms of trophoblastic tissue (intermediate
trophoblast and syncytiotrophoblast).
            Syncytiotrophoblast is a unique multi nucleated layer, lacks
proliferative capacity and is maintained by fusion of underlying
cytotrophoblast cells. They massively increase the surface area available for
nutrient exchange between the mother and the fetus.
5Intermediate trophoblasts are thought to be the cell of origin for
Exaggerated placental site (EPS),Placental site nodule (PSN),Placental site
trophoblastic tumour (PSTT) and Epithelioid trophoblastic tumour (ETT).
Gestational trophoblastic disease represents a form of proliferation of
trophoblasts.
              Malignant-like behaviour is tightly controlled in healthy trophoblast.
However, in gestational trophoblastic disease the regulatory mechanisms fail,
resulting in tumors that are highly invasive, metastatic and very vascular.
Molar pregnancies are subdivided into complete mole (CM) and partial
mole (PM) based on cytogenetic, histopathological and clinical features.
CM are diploid and androgenic in origin .CM  arise  as a consequence
of  duplication of a single sperm  following fertilization of an empty ovum
(75-80%)  or dispermic  fertilization of an empty ovum (20-25%).
         PM are usually triploid (90%) in origin by dispermic fertilization of
ovum. 10% of PM are tetraploid or mosaic conceptions.
        Morphological distinction of non-molar miscarriage from partial
hydatidiform mole can be difficult. P57kip2 is expressed by the maternal
allele and is visible on histology as nuclear staining of cytotrophoblast of all
gestations apart from androgenetic complete mole. Additionally, ploidy
analysis by flow cytometry can distinguish diploid from triploid conceptions,
helping to diagnose partial mole.
Figure - 1
Gross photograph of  hydatidiform mole
6CLINICOPATHOLOGIC FEATURES OF
GESTATIONAL TROPHOBLASTIC DISEASE
GTD Pathologic features Clinical features
Hydatidiform mole,
Complete
46,XX (mainly); 46,XY
Absent fetus/embryo
Diffuse swelling of villi
Diffuse trophoblastic
hyperplasia
15-20% trophoblastic  sequelae
? hCG often  >100,000 mIU/mL
Medical complications common
Hydatidiform mole,
partial
Triploid (69, XXY; 69,
XYY; 69 XXX)
Abnormal fetus/embryo
Focal swelling of
villi/trophoblast inclusions
Focal trophoblastic
hyperplasia/scalloping of
villi
<5% trophoblastic sequelae
?hCG usually<100,000mIU/mL
Rare medical complications
Invasive Mole
Myometrial invasion
Swollen villi
Hyperplastic trophoblast
15% metastatic to lung/vagina
Most often diagnosed clinically,
rather than pathologically
Choriocarcinoma
Abnormal trophoblastic
hyperplasia and anaplasia
Absent villi
Hemorrhage, necrosis
Vascular spread to distant sites–
lung/brain/liver
Malignant disease
PSTT
Tumor cells infiltrate
myometrium with
vascular/lymphatic invasion
Intermediate cells present
Absent villi
Less hemorrhage and
necrosis,Tumor cells stain
positive for hPL
Extremely rare
? hCG levels less reliable
indicator
Relatively chemoresistant
Mainly surgical treatment
Figure - 2
Photomicrograph of complete hydatidiform mole demonstrating a
markedly edematous villus with central cisternae formation
Figure - 3
Photomicrograph of a partial mole
7Approximately 10-17% of hydatidiform mole will result in invasive
mole which arises from myometrial invasion of a hydatidiform mole via
direct extension through tissue or venous channels. Invasive mole is
characterized by the presence of edematous chorionic villi while
choriocarcinoma lacks villi formation.
Placental-site trophoblastic tumors grow more slowly; can arise after
any type of pregnancy. Histological analysis is needed to substantiate the
diagnosis.
Placental-site trophoblastic tumours, represents 0·2% of gestational
trophoblastic diseases and arise from intermediate trophoblast of the placental
implantation site.
Epithelioid Trophoblastic Tumor – ETTs are the most recently
described and rarest of trophoblastic tumors. It is composed of chorionic type
intermediate trophoblast and is distinct from both CC and PSTT with
distinctive hyalinization. Most ETTs present many years after a full-term
delivery.
ETT usually presents as a discrete uterine mass and stains diffusely
positive with PLAP (placental specific alkaline phosphatase), cytokeratin, p63
and inhibin ? whereas ? hCG and hPL positivity is weak and scattered.
Figure - 4
Invasive mole with direct extension of molar tissue, including
hydropic villi and covering hyperplastic  trophoblast, into the myometrium
Figure - 5
Photomicrograph of epithelioid trophoblastic tumor
8ETT is truly a rare but distinct trophoblastic tumor rather than   just a
morphological variant of PSTT, although the biological behavior appears
similar .In contrast to placental site trophoblastic tumor, the cells of ETT are
smaller and display less nuclear pleomorphism. In addition, ETT grows in a
nodular fashion compared with the infiltrative pattern of placental site
trophoblastic tumor.
MOLECULAR PATHOGENESIS
Genomic imprinting is believed to play a pivotal role in
the pathogenesis of hydatidiform mole. Similar to other human cancers,
malignant transformation in gestational trophoblastic tumors is likely a
multistep process and involves multiple genetic alterations including
activation of oncogenes and inactivation of tumor suppressor genes.
 In addition, expression of telomerase activity, altered expression of
cell-cell adhesion molecules and abnormal expression of matrix
metalloproteinase have also been reported for in the pathogenesis of
malignant transformation of GTD. These represent disruption of the delicate
balance and regulation of cellular processes including proliferation,
differentiation, apoptosis and invasion.
In complete mole, strong expression of epidermal growth factor
receptor (EGFR) and c-erbB3 in the extra villous trophoblasts was
significantly associated with the development of post molar tumor.
9Marked down regulation of heat shock protein 27 in gestational
trophoblastic tumors contributes to the marked sensitivity of the tumor to
chemotherapy.
HUMAN CHORIONIC GONADOTROPHIN (HCG)
 hCG is a disease-specific tumor marker produced by hydatidiform
mole and gestational trophoblastic neoplasms.
It is easily measured quantitatively in both urine and blood, and hCG
levels have been shown to correlate with the burden of the disease.
It is a placental glycoprotein composed of 2 dissimilar subunits: an  ?
subunit of 92 amino acids resembling that of the pituitary glycoprotein
hormones and a ? subunit of 145 amino acids that is unique to placental
production.
Although accurate measurements of ? hCG levels are invaluable in
diagnosing and later monitoring GTD, some laboratory assays may yield
false-positive ? hCG results.
These so-called phantom hCG with levels reported as high as
800 mIU/mL, have led to treatment of healthy patients with unnecessary
surgery and chemotherapy.
The heterophile (human antimouse) antibodies are found in 3-4% of
healthy people and can mimic ? hCG immunoreactivity
10
There are 3 ways to determine whether hCG assays are falsely positive
when there is a clinical suspicion of phantom hCG:
(1)  Determine urine hCG level, which should be negative because the
interfering substances are not excreted in urine;
(2)  Request serial dilution of the serum, which should not show a parallel
decrease with dilution; and
(3)  Send the serum and urine of the patient to an hCG reference laboratory.
Additionally, there is some cross-reactivity of ? hCG with luteinizing
hormone (LH), which may lead to falsely elevated low levels of ? hCG.
Measurement of LH to identify this possibility and suppression of LH
with oral contraceptive pills will prevent this problem.
“Quiescent gestational trophoblastic disease” is a term applied to a
presumed inactive form of GTD that is characterized by persistent,
unchanging low levels (200 mIU/mL) of “real” ? hCG for at least 3 months
associated with a history of GTD or spontaneous abortion, but without
clinically detectable disease. The ? hCG levels do not change with
chemotherapy or surgery. Follow-up of patients with presumed quiescent
GTD reveals subsequent development of active GTN in about one-quarter.
According to the International Society for the Study of Trophoblastic
Diseases 2001 recommendations
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1. False-positive ? hCG resulting from heterophile antibodies or LH
interference should be excluded.
2. The patient should be thoroughly investigated for evidence of disease,
immediate chemotherapy or surgery should be avoided.
3. The patient should be monitored long term with periodic ? hCG testing
while avoiding pregnancy.
4. Treatment should be undertaken only when there is a sustained rise in
? hCG (3000mIU/ml) or the appearance of overt clinical disease.
5. To exclude pituitary hCG which is mostly found in older peri
menopausal women, and is completely benign and can be resolved
using hormone replacement therapy for 3 weeks.
DIAGNOSIS OF GTN
FIGO standardized the criteria used for the diagnosis of   GTN (Ngan
HY et al)
1. ? hCG levels plateau plus or minus 10% of baseline recorded over a
period of  three consecutive weeks (1,7,14,21 days).
2. ? hCG levels rise  greater than 10% of baseline recorded  over a period
of  two  consecutive weeks ( days 1,7,14).
3. Persistence of detectable ? hCG for more than 6 months after molar
evacuation.
4. Histological evidence of choriocarcinoma.
12
WORK UP OF PATIENT WITH GTN
Women newly diagnosed with GTN require a thorough evaluation of
the extent of their disease such that the appropriate treatment can be selected.
This evaluation includes a history and physical examination, serum
quantitative ?hCG level, a complete blood count, and hepatic and renal
function tests.
A pelvic ultrasound is often useful to detect the extent of uterine
involvement and may identify patients who are at risk for uterine perforation
or who would benefit from a hysterectomy to reduce tumor burden.
A chest X-ray should be obtained to evaluate lung metastasis. If this is
negative, and lung metastasis suspected in symptomatic patients, chest
computed tomography (CT) scan may be performed since it may detect micro
metastases in 40% of patients with a negative chest X-ray.
Additional imaging can be omitted in patients with a negative chest CT
given that distant metastases are unlikely in the absence of lung metastases.
Conversely, abdominal and brain imaging are an essential part of the
workup in patients with metastases to the vagina or to the lungs and in
patients with a histological diagnosis of choriocarcinoma.
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Furthermore, an elevated cerebral spinal fluid/plasma ? hCG ratio may
suggest cerebral involvement. Additional imaging, such as FDG-PET scan,
may be useful to accurately outline sites of metabolically active metastases
and help determine the potential for tumor resectability.
REVISED FIGO 2000 RISK SCORING AND ANATOMIC STAGING
Bagshawe first introduced risk scoring in 1974 for malignant
trophoblastic disease. Since 2002, all physicians treating gestational
trophoblastic neoplasia should use FIGO system to allow comparison of data.
 The combined prognostic score predicts potential for development of
resistance to mono chemotherapy with methotrexate or actinomycinD.
A score of 0–6 suggests low risk of resistance and 7 or more indicates
high risk of resistance to chemotherapy. Low risk GTN cases are treated with
single agent chemotherapy. High risk disease has almost no chance of being
cured with mono chemotherapy and needs multidrug treatment.
Anatomical staging does not aid therapeutic choices but helps
clinicians to compare results between centers.
Patients should have doppler pelvic ultrasonography to measure the
uterine tumor size and volume, local spread of disease within the pelvis, and
disease vascularity. Disease vascularity can suggest patients who are at risk of
treatment resistance.
Figure  - 9
Chest X ray showing pulmonary metastasis in GTN
Figure  -10
Doppler ultrasound examination of a complete hydatidiform mole
with a vascular uterine mass
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FIGO ANATOMIC STAGING FOR GTN
Stage 1 - Disease is confined to uterus
Stage 2 - Disease extends to the genital tract
Stage3 – Disease spread to lungs with or without extension to the genital
tract
Stage 4 - Disease spread to all other metastatic sites like brain, kidneys
and liver
International Federation of Gynecology and Obstetrics (2000)
Scoring System for Gestational trophoblastic neoplasia by prognostic factors
0 1 2 4
Age(years) <40 >40
Antecedent
pregnancy
Mole Abortion
Term
pregnancy
Interval from
antecedent
pregnancy to
chemotherapy
(months)
<4 4-6 7-12 >12
? hCG concentration
(IU/L) <10
3 103 – 104 104 – 105 >105
Number of
metastasis 0 1-4 5-8 >8
Site of metastasis Lung
Spleen,
Kidney
Gastro
intestinal tract
Liver,
Brain
Largest tumor
mass diameter (cms)
- 3-5 >5 -
Previous
Chemotherapy - - Mono therapy
Combined
therapy
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Gestational trophoblastic diseases are tumor and tumor like condition
that originate from the fetal chorion. Trophoblastic tumors are fetal allograft
in maternal tissues and present unique biological, immunological and
pathological problems.
INCIDENCE
The reported incidences of hydatidiform mole vary widely in different
regions of the world.
Incidences are highest in South East Asia, Indonesia, India and Turkey
with rates ranging from 2 to 12 per 1000 pregnancies6.
Estimates from studies in North America, New Zealand and Australia
have shown the incidence to range from 0.57 to 1.1 per 1000 pregnancies7.
In UK, the incidence of GTD is 1 in 714 live births.1
A hospital based study by Tham BW et al from England and North
Wales shows the women of Asian descent have two to three fold higher rates
of  hydatidiform mole compared with  non Asian women (1/387 vs1/752). 16
The high incidence in certain population has been attributed to socio
economic and nutritional factors and not due to genetic traits and cultural
factors (John RL et al) 7.
REVIEW OF LITERATURE
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Patient score is a total of individual scores of the eight prognostic
factors. PSTT should not be scored but needs to be staged.
COEXISTENT MOLE AND FETUS
Coexistence of a fetus with molar change of the placenta is relatively
rare, occurring in 1 of 22,000–100,000 pregnancies.
Medical complications of hydatidiform mole appear to be increased.
Studies show that compared with singleton hydatidiform mole, twin
pregnancies with fetus and mole has increased risk for post molar GTN.
Major congenital abnormalities have not been reported in surviving
infants. Prenatal invasive testing for fetal karyotype should be considered in
cases where it is unclear if the pregnancy is a complete mole with a coexisting
normal twin or a partial mole.
The outcome for a normal pregnancy with a coexisting complete mole
is poor, with approximately a 25% chance of achieving a live birth.
There is an increased risk of early fetal loss (40%) and premature
delivery (36%).
The incidence of pre-eclampsia is variable, with rates as high as 20%
reported.
17
As per a study by Kim SJ et al from Korea, the hospital based
incidence of molar pregnancies has declined from 40 per 1000 deliveries
during 1970s to 2 per 1000 deliveries during 1990s17.
The reduction in incidence is due to increased socioeconomic status,
changes in diet and maternal age at child birth, fall in birth rates, changes in
diagnostic accuracy, and reporting variations (Berkowitz RS et al). 9
AGE
Advanced or very young maternal age has consistently been correlated
with higher rates of complete mole (Lybol C et al 2011).18
Compared to women aged 21 to 35 years, the risk of complete mole is
1.9 times higher in women more than 35 years and less than 21 years of age
and is 7.5 times higher in women greater than 40 years of age (Sebire NJ et
al).19Abnormal fertilizations are common in ova from women of extremes of
age.
In a study by Kumar N et al, major risk factor for complete mole is age
more than 30 years (RR 3.9).20
In women over the age of 50 years one out of three pregnancies are
molar (Berkowitz RS) 9.
Age is less likely to be a factor for partial mole (Parazzini et al) 22.
Figure - 8
Karyotype derivation of complete and partial hydatidiform mole and rare
biparental repetitive complete hydatidiform mole.
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Another obstetric risk factor for complete and partial mole is a history
of spontaneous abortion. There is a 2 to 3 fold increased risk of   molar
pregnancy in women with a history of   spontaneous miscarriage (Parazinni
F et al) 22.
Difficulty in conception and infertility problems are associated with
odds risk of 2.4 and 3.2 respectively for complete and partial mole (Berkowitz
RS) 9.
Among the environmental factors, only consistent association has been
an inverse relationship between beta carotene and animal fat dietary intake
and the incidence of complete molar pregnancies. Diet can reset the genetic
imprint (Lurain JR et al) 7.
Risk of partial mole appears to be associated with reproductive
history like use of oral contraceptives and a history of irregular menstruation
but not with dietary factors or maternal age (Berkowitz RS et al) 26.
The risk of gestational trophoblastic neoplasia is related to hormonal
factors and is increased in women with light menstrual flow and menarche
after the age of 12 years (Berkowitz RS et al).9
CLINICAL FEATURES
In recent years, the availability of ultrasound and sensitive ? hCG tests
has meant a change in the clinical presentation to earlier detection at a
gestational age of 10–12 weeks (Nienke EVT et al) 6.
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In UK, greatest number of GTD cases (80%) occurred between the
ages of 20 to 39 years (Pisal N et al) 2.
In a study from All India Institute of Medical Sciences, New Delhi by
Hari Prasad R et al, the mean age of presentation of GTD was 28.2 years21.
RISK FACTORS
Prior hydatdiform mole predisposes to another molar pregnancy. The
risk of repeat molar pregnancy after one mole is about 1% or about 10 to 20
times the risk of general population (Berkowitz RS) 9.
After two molar gestations the risk of third mole is 15 to 20 % (Garett
LA et al) 23.
Recurrent molar pregnancies are autosomal recessive condition with
biparental diploid chromosomes and have significant under expression of p52
(KIP2) which has important role in apoptosis and tumor expression (Fisher
RA et al) 24.  Risk is not decreased by change in partner.
Familial clusters of biparental repeat complete mole are associated
with novel missense NLRP7 gene mutation on chromosome 19q13.3-13.4.
The function of the normal protein and the mechanism by which
mutations are associated with imprinting abnormalities are not known (Fisher
RA et al) 24.
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Respiratory distress caused by trophoblastic embolisation is rare and
observed around the time of molar evacuation among patients with uterine
enlargement greater than 14 to 16 weeks size (John T S et al) 4.
With routine first trimester ultrasonography, a significant proportion of
patients (41%) are asymptomatic at the time of diagnosis (Johns J et al) 29 and
may present sonographically as early pregnancy failure or anembryonic
pregnancy. This highlights the importance of histological examination of the
products of conception of anembryonic pregnancies (Fowler DJ et al) 30.
Estimation of ? hCG values may be of value in diagnosing molar
pregnancies (? hCG greater than 2 multiples of median).
Partial mole present with symptoms of missed or incomplete abortion
like vaginal bleeding (75%) and are usually diagnosed by histological review
of curettage specimen (Berkowitz RS) 9.
A urine pregnancy test should be performed in all cases of persistent or
irregular vaginal bleeding after a pregnancy event.
 Symptoms of metastatic disease such as dyspnoea, hemoptysis, chest
pain, headache, seizures, hemiparesis can occur very rarely (RCOG
GTG 38)1.
The prognosis of women with GTN after a non molar pregnancy is
worse due to delay in diagnosis or advanced disease at presentation (RCOG
GTG  38)1.
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The classic clinical features of molar pregnancy are irregular vaginal
bleeding, vomiting, excessive uterine enlargement, and early failed pregnancy
(RCOG GTG 38)1.
Vaginal bleeding is the most common presenting symptom in patients
with complete mole occurring in 80 to 90% of cases.
Currently anemia is present in only 5%of cases due to occult bleeding.
Vomiting requiring antiemetic therapy is present in 8% of patients due to high
? hCG values (Savage P et al) 8.
Uterine enlargement greater than the expected dates is present in 28%
of patients and is due to retained blood and trophoblastic proliferation.
Pre eclampsia occurs less frequently (1%) because of earlier diagnosis.
(Gemer O Segal et al) 27.
7% patients with GTD had biochemical hyperthyroidism and 2% had
clinical hyperthyroidism (Walkington et al) 28.
Bilateral theca leutin cyst enlargement of the ovaries occurs in
approximately 15% of cases. (? hCG levels> one lakh   IU/ml). The resolution
of theca leutin cysts lags behind the drop of ? hCG and may take several
months to resolve after molar evacuation but rarely require surgical
intervention for torsion or rupture (Hou JL et al)31.
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DIAGNOSIS
The routine use of ultrasound in early pregnancy has probably led to
the earlier diagnosis of molar pregnancies. The accuracy of ultrasound
diagnosis of molar pregnancy is increased with increasing gestational age, 35
to 40% before 14 weeks to 60% after 14 weeks (Fowler DJ et al).30
The ultrasound finding of cystic spaces in the placenta and a ratio of
transverse to anteroposterior dimension of gestational sac greater than 1.5 has
a positive predictive value of 87% in the diagnosis of partial mole (Finc C et
al) 32.
In the second trimester, complete mole is recognized in ultrasound as
numerous vesicular structures filling the uterine cavity often with a snow
storm appearance.
Patients with molar pregnancies have markedly elevated pre
evacuation ? hCG values
In GTD, several forms of  hCG (6 major variants)   exist, free ? hCG,
free ? hCG, hypergycosylated hCG , ? core hCG, nicked free ? hCG, absent
C terminal peptide (Cole LA  et al) 33.
In the UK, non commercial rabbit polyclonal   antibody that detects all
forms of ? hCG with low false negative rate is used. The only commercial
assay that is comparably safe is Siemens Immulite (Deerfield, IL, USA) (Cole
LA et al) 34.
Figure - 13
Pelvic ultrasound of complete hydatidiform mole with
characteristic vesicular pattern of multiple echoes
Figure 14
Ultrasound and MRI of a complete hydatidiform mole and healthy co-twin
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High rates of hyperglycosylated hCG variant to total hCG can detect
malignant forms of GTD (Cole LA et al) 34.
Free ? hCG is a marker for PSTT (Harvey RA et al) 35.
SURGICAL EVACUATION
Suction curettage is the method of choice of evacuation for molar
pregnancies. When the size of fetal parts deters the use of suction curettage in
partial mole, medical evacuation can be used.
Anti D prophylaxis is required following evacuation of molar
pregnancy in Rh negative women (RCOG GTG 38)1.
Medical evacuation of complete mole should be avoided if possible
(Tidy J et al) 36.
Hysterectomy is rarely recommended but might be considered for
women who have completed families, or have life threatening hemorrhage or
sepsis or in stage1 PSTT (Elias K et al) 37.
Although hysterectomy stops the risk of local invasion, it does not
eliminate the risk of GTN (3 -5%) and ? hCG monitoring should still be done
(Lurain JR et al) 7.
Preparation of cervix with prostaglandins immediately prior to
evacuation is safe. Prolonged cervical preparation with prostaglandins is
avoided to reduce the risk of trophoblast embolisation (RCOG GTG 38)1.
Figure – 11
Serum ß-hCG following uterine evacuation12
Figure - 12
Suction curettage of molar pregnancy12
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The use of oxytocin infusion prior to the completion of evacuation is
not recommended in view of trophoblast embolisation.
In the presence of significant hemorrhage, the need for oxytocin
infusion weighed up against the risk of embolisation of trophoblast cells
(RCOG GTG 38)1.
The histological examination of material obtained from the medical or
surgical evacuation of all early failed pregnancies is recommended to exclude
GTD (Well M et al) 38.
A urine pregnancy test should be performed 3 weeks after medical
management of early failed pregnancy if products of conception are not sent
for histological examination (Seckl MJ et al) 39.
There is no need to routinely send products of conception for
histological examination following therapeutic termination of pregnancy
provided fetal parts have been identified on prior ultrasound examination
(RCOG GTG 38)1.
There may be a role for second evacuation in persisting vaginal
bleeding after molar evacuation in selected cases after ultrasound examination
and ? hCG values less than 5000 U/li (Pezeshki M et al) 41.
Consultation with a specialized center for treating GTD is
recommended prior to second evacuation.
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Biopsy of a vaginal lesion suggestive of a gestational trophoblastic
tumor is dangerous because of the massive bleeding that may occur
(Berry E et al) 40.
POST MOLAR SURVEILLANCE
Serial quantitative serum ? hCG determinations should be done after
molar evacuations using standard assays (<5mIU/ml) every 1-2 weeks till it
becomes not detectable, then every 1-2 months for an additional 6-12 months
(ACOG practice bulletin no. 53, 2004) 11.
If ? hCG has reverted back to normal within 56 days of pregnancy
event, then follow up will be for 6 months from the date of uterine evacuation.
If ? hCG has not reverted back to normal, within 56 days of pregnancy
event, then follow up will be for 6 months from the normalization of ? hCG
levels (Sebire NJ et al) 42.
Normalisation of serum ? hCG after molar evacuation is within 6
weeks in 5% of patients and within 11 weeks in 50% of patients and within 25
weeks in 95% of patients (Yedema KA et al) 43.
PROPHYLACTIC CHEMOTHERAPY
Prophylactic Chemotherapy at the time of or immediately after molar
evacuation is associated with reduction in incidence of GTN from 15 -20% to
3-8%.
26
The use of prophylactic chemotherapy is limited to special situations
like high risk cases where follow up is not possible.
It can cause chemo resistance and adverse side effects and it does not
completely eliminate the need for follow up.
Treating many patients to prevent a few GTN does not offer significant
advantages over post evacuation follow-up (Limpongsanurak S et al) 44.
The low morbidity and mortality achieved by monitoring patients with
serial ? hCG determinations and instituting chemotherapy only in patients
with post molar gestational trophoblastic disease outweighs the potential risk
and small benefit of routine prophylactic chemotherapy (John TS et al) 4.
CONTRACEPTION
Women should be advised not to conceive until their follow up is
complete. Two randomized control trials from NETDC and GOG shows oral
contraceptive pills (OCPs)  does not increase the risk of GTN (Costa HLF et
al 2006) 45.
The   conflicting data from a case series in UK showing increased risk
of GTN in OCP users before ? hCG levels are normal is explained by the
higher dose of estrogen (> 50 micrograms) in OCPs (Stone M et al 1979)46.
OCPs are preferable because they have the advantage of suppressing
endogenous LH which may interfere with ? hCG measurements.
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OCPs are safe for use during the entire period of follow up (Gerulath A
H et al) 10. Intrauterine contraceptive devices should not be used because of
the risk of uterine perforation.
RISK OF GTN
The likelihood of GTN is increased to 40% with pre evacuation ? hCG
more than a lakh mIU/ml,  uterine size more than 20 weeks, theca luetin cysts
more than 6 centimeters in diameter compared to 4% without any of these
signs.
Patients more than 40 years, repeat molar pregnancy, heterozygous
complete mole, aneuploid mole, mole with medical complications like
preeclampsia, hyperthyroidism and trophoblastic embolisation are at
increased risk of GTN (Berkowitz RS) 47.
The use of a normal uneventful ? hCG regression corridor (>95th
percentile) together with FIGO criteria for diagnosis of   GTN   facilitates
early diagnosis (2 weeks before) and more expectant management of GTN
(Behtah N et al) 48.
CHEMOTHERAPY
The landmark publication of Li et al in 1956, describes the success of
methotrexate in treating gestational trophoblastic neoplasia.
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Bagshawe and his associates first used EMA-CO in 1984 to treat
malignant trophoblastic disease.
Indications for chemotherapy in UK include FIGO criteria for GTN,
heavy vaginal or gastrointestinal or intraperitoneal bleeding, metastasis more
than 2 centimeters diameter in the lungs and vagina, ? hCG more than 20,000
one month after evacuation (Seckl MJ et al) 5.
For most low risk GTN patients, monochemotherapy with
methotrexate or actinomycin D is the preferred treatment (Alazzam M et al)49.
The commonly used regimens are weekly intramuscular methotrexate
50mg and oral folinic acid 15 mg, 30 hours after methotrexate (or)
methotrexate 50 mg intramuscularly every 48 hours alternating with oral
calcium folinate 15 mg each 4 doses every 2 weeks.
Most patients are treated at home after a short stay in hospital to
monitor for bleeding.
About 2% of women treated experience side effects like mouth ulcers
or pleuritic and peritoneal pains from serosities and gastrointestinal
disturbances.
If ? hCG values have not fallen by at least 10% over a cycle of therapy,
treatment should be changed to an alternative single-agent regimen. Patients
who develop resistance to methotrexate can be switched to D-actinomycin if
?  hCG concentrations < 100IU/li or multidrug chemotherapy if ? hCG> 100
IU/li (Seckl M et al)5 .
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Chemotherapy should be continued until ? hCG is normal and for a
further 6 weeks to eliminate residual disease or relapse (Growdon WB et al) 5.
Low risk GTN patients scoring 5-6 with increased vascularity in
doppler or ? hCG > 4 lac IU/li is unlikely to be cured by monotherapy, hence
multidrug regimens should be given from the outset. Overall survival is 100%
in low risk GTN (McGrath et al) 50.
For high risk GTN cases, EMA-CO regimen every 2 weeks is
effective worldwide with predictable and manageable short term side effects
(Bagshawe KD et al). 51
EMA-CO regimen necessitates overnight stay every two weeks, causes
reversible alopecia and myelosuppression (filgrastim helps maintain
neutrophil count and avoids febrile neutropenic episodes).
Long term survival is 27% in liver metastasis, 70% in brain metastasis,
and 10% in both site metastases.
Most of high risk metastatic cases presented late with widespread
disease, most had not had a molar pregnancy, and most were not registered
for follow up.
Chemotherapy is continued for 6 weeks after normal ? hCG or 8 weeks
if brain or liver metastasis is present.
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In drug resistant cases EMA-EP regimen is used. If patient fails to
respond to methotrexate containing  regimens , paclitaxol containing regimens
alternating TE/TP every 2 weeks or ifosfamide containing regimens VIP or
ICE is used (Wang J et al). 52
        12.5% of high risk GTN cases will develop recurrence after initial
remission (Soper JT et al) 4.
TREATMENT OF METASTASES
Cranial radiotherapy is given concurrently with the initiation of
chemotherapy with or without intrathecal  methotrexate  to shrink brain
metastasis and to  minimize intracranial bleeding.
Craniotomy and resection of drug resistant solitary lesions is very
rarely indicated who do not have metastatic disease elsewhere (Synman
LC et al) 12.
Hepatic resection and/or selective embolisation of the hepatic arteries
may help in liver metastasis to control bleeding or remove resistant tumor.
A solitary chemoresistant pulmonary nodule can be treated with
thoracotomy and wedge resection after ruling out other systemic metastases.
Vaginal metastases can cause heavy bleeding which can be controlled
by packing. Alternatively, embolisation of the vaginal branch of the
hypogastric artery can be considered (Synman LC et al) 12.
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PSTT
The stage, ? hCG, mitotic index, and duration of more than 4 years
from preceding pregnancy were prognostic for PSTT.
Only time from previous pregnancy to first treatment remained
predictive of survival. This effect was not explained by differences in disease
stage or ? hCG concentrations, but might suggest a biological switch in
tumors after this time.
Management of placental-site trophoblastic tumour differs from that
for choriocarcinoma (Schmid P et al). 53
Patients with metastatic disease need combination chemotherapy (eg,
EP-EMA) until 8 weeks of normal ? hCG concentrations are recorded.
Residual masses are removed surgically, including the uterus, which
can contain microscopic disease with sampling of pelvic lymph nodes and
ovarian conservation, unless the patient has a family history of ovarian cancer
or is postmenopausal (Taymaa May et al)14 .
The adjuvant therapy after hysterectomy is 8 weeks of EP-EMA or
TE/TP when there are poor risk factors such as disease presentation beyond 4
years from the antecedent pregnancy.
Hysterectomy is the first line of treatment in women with Stage 1
PSTT and ETT (Taymaa May et al) 14.
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POST CHEMOTHERAPY SEQUALAE   AND FOLLOW UP
Nearly all side effects of chemotherapy are reversible. Pregnancy rate
after chemotherapy is more than 83% (Woolas RP et al) 54. Incidences of
congenital malformations are not increased in babies (1.8%). The rate of still
birth (18.6/1000 births) is elevated compared with normal population (RCOG
GTG 38).1
Patients are advised not to become pregnant until 12 months after
completion of chemotherapy to reduce teratogenicity and to avoid confusion
between a new pregnancy and relapsed disease.
The age of menopause is advanced by one year in patients who receive
monotherapy and by 3 years in patients if they receive multidrug therapy.
Women with high risk GTN treated with etoposide containing multi
drug regimens are at increased risk of developing secondary cancers, if they
survive more than 25 years after chemotherapy (Relative Risk (RR) 16.6 for
AML, RR 4.6 for colon cancer, RR 5.79 for breast cancer, RR 3.4 for
melanoma) (Rustin GJS et al) 55.
If etoposide containing multidrug chemotherapy is limited to less than
6 months, there is no increased risk of developing secondary cancers.
The patients are followed up for a period of one year in low risk GTN
and 2 years after completion of chemotherapy in high risk GTN cases because
of late recurrence
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 If patients become pregnant after a molar pregnancy, early ultrasound
examination is done to ensure healthy pregnancy and to rule out repeat mole.
Serum ? hCG is done at 6 weeks and 10 weeks at the end of any future
pregnancy event after GTD to exclude disease recurrence. The pathologic
examination of placentas and other products of conception are recommended
in all future pregnancies.
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A  prospective study of Gestational trophoblastic disease  from one of
the largest tertiary referral center in Tamil Nadu ,The Institute of Obstetrics
and Gynecology, Madras Medical College, Chennai, conducted over a period
of one year ( May 2010 to April 2011) covering 114 patients.
? Estimation of the incidence of molar pregnancies at IOG.
? Estimation of the incidence of post molar trophoblastic
neoplasia among the molar pregnancies.
? Descriptive analysis of the epidemiological factors, natural
history, treatment and outcome of GTD patients at IOG.
MATERIALS AND
METHODS
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? Setting
Institute of Obstetrics and Gynecology, Egmore , Chennai – 600 008.
? Collaborating Units
           Department of Medical Oncology, IOG
           Department of Pathology, IOG
?  Design
Prospective longitudinal Descriptive Study
? Statistical Analysis
 Frequency distribution of variables and log value regression curve
from the means and standard deviation of serial monthly ? hCG values
of uneventful molar pregnancies and GTN using SSPN.
? Period
May 2010- April 2011
? Study Population
           All women with GTD attending IOG during May 2010-April 2011
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INCLUSION CRITERIA
? Women admitted in IOG with complete mole, partial mole, invasive
mole, choriocarcinoma, placental site trophoblastic tumor and
epithelioid  trophoblastic tumor.
? Women with persistent and malignant trophoblastic diseases referred
to IOG for tertiary care.
METHODOLOGY
?  Standardized protocols are followed for registration, assessment,
treatment and follow up of patients with molar pregnancy attending
IOG.
? After getting informed consent, women are interviewed, examined and
registered as per standard clinical guidelines.
? A Record is maintained regarding information on
1. History
2. Physical examination
3. Ultrasound
4. Initial ? hCG and subsequent values
5. Chest x-ray
6. Histological diagnosis
7. Evacuation details
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8. Pretreatment WHO Risk Score and
9. Details of Chemotherapy if given
? Suction evacuation is the procedure of choice.
? Patients are advised to use oral contraceptives after evacuation for the
follow up period.
? At follow up, patients are examined clinically and serum ? hCG is
done at regular intervals, and imaging procedures are done if needed.
? In asymptomatic patients serial serum ? hCG is measured once in 4
weeks and in symptomatic patients serial serum ? hCG is done once in
2 weeks during follow up period.
? After ? hCG value normalizes, patients are followed up for a period of
12 months in uneventful cases.
?   Low risk GTN cases   are followed up for a period of one year after
completion of single agent chemotherapy.
? High risk GTN cases are followed up for a period of 2 years in GTN
cases after completion of multi agent chemotherapy.
? In our study, we have followed up the patients till September 2011.
? The  data collected are analyzed using  statistical  methods for the
estimation of the incidence of  molar pregnancies  at IOG
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? Epidemiological factors, natural history and follow up of molar
pregnancies   are descriptively analyzed.
? The incidence of persistent post molar trophoblastic diseases among
molar pregnancies (high risk and low risk) and their response to
chemotherapy (single and multiple agents), the dynamics of ? hCG
fall and the outcome of treated patients are studied.
OBSERVATION AND
ANALYSIS
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     RESULTS
Total number of  GTD cases 114
Cases at IOG 102
Referral cases 12
Referral cases
                                               ISO-KGH -3
                                               RSRM              -1
                                      Private hospitals         -6
                                    Arakkonam GH            -1
                                                    KMC           -1
Total referral          -12
Cases at IOG (102)
Total GTD 102
Normal Molar pregnancies 90
Low risk GTN 12
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This observational study is a hospital based study and not population
based. During the study period there were a total of 20,275 pregnancies in the
Hospital for Women and Children, Egmore, Chennai. The pregnancies
include abortions both induced and spontaneous, live births, intrauterine
deaths, spontaneous expulsions, still births, and ectopic pregnancies.
Total number of cases during the study period is 114 of which 12 cases
were evacuated outside and   referred for tertiary care.
102 cases of GTD were treated and followed up at IOG (chart -1).
 Incidence of molar pregnancies is 5 per 1000 pregnancies at our
institution.
Of the 102 cases, 12 cases were low risk GTN and 90 cases were
benign molar pregnancies.
Total number of GTD cases at IOG -102
Complete mole 80 78.4%
Partial mole 21 20.6%
Of the total GTD cases at IOG, 78.4% were complete mole and 20.6%
were partial mole (Chart 2).
Chart -1:
TOTAL GTD CASES   -114
Chart -2:
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Of the 12 low risk GTN cases at IOG, 10 cases (83.4%) were following
complete mole and one low risk GTN case (8.3%) was following partial mole.
Among the low risk GTN cases at IOG, there were 5 cases (41.6%) of
invasive mole.
One case (8.3%) of epithelioid trophoblastic tumor presented 10 years
after last child birth. There was no case of high risk disease at IOG.
REFERRAL CASES
Referral cases (12) formed 11% of total cases and 50% of gestational
trophoblastic neoplasia. Of the referral cases 2(16.6%) were high risk
metastatic GTN cases following term pregnancies and 10 were low risk GTN
cases (83.3%).
Of the low risk GTN cases referred, 7 cases (58.3%) were following
complete mole and 2 cases (16.6%) were following partial mole. One case
(8.3%) was following missed abortion (Chart-3).
ANTECEDENT PREGNANCY
The antecedent pregnancy was hydatidiform mole in 83.3% cases of
low risk GTN except the ETT in which the live birth was remote (Chart-4).
The antecedent pregnancy was abortion in one case of low risk
GTN (4.1%).
Chart-3:
REFERRAL CASES (12)
                                                         Chart-4:
ANTECEDENT PREGNANCY IN 24 TREATED GTN CASES
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The antecedent event was full term pregnancy in both high risk
metastatic GTN cases and low risk epithelioid trophoblastic tumor (12.5%).
AGE DISTRIBUTION OF WOMEN WITH GTD
Most cases (81%) presented between 20- 29 years which is the peak
fertility group (mean24.5 years). 9% of the cases were below 20 years and
another 9% of cases were above 30 years. Only one case presented beyond 40
years of age (chart-5).
Age Group No. of Cases Percentage
Below 20 years 11 9.5%
20 to 29 years 92 81%
30 to 39 years 10 8.6%
More than 40 1 0.9%
PARITY OF WOMEN WITH GTD
In 31.5% of cases, molar pregnancy was their first conception. It is
after one live birth in 31.5% of cases and two live births in 21% of cases.7%
(8 cases) of molar pregnancies were after an abortion and there were four
(3.5%) repeat molar pregnancies.
Chart 5:
AGE DISTRIBUTION OF WOMEN WITH GTD
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PARITY NO. OF CASES PERCENTAGE
Primi 36 31.5%
Gravida 2 36 31.5%
Gravida 3 24 21%
Gravida 4 5 4.3%
Gravida 6 1 0.8%
Abortion 8 7%
Repeat mole 4 3.5%
Three out of the four repeat mole (75%) had developed post molar GTN.
PRESENTING SYMPTOMS
In 51% of the cases the molar pregnancy was diagnosed in routine
early first trimester ultrasound in asymptomatic women with history of
amenorrhea. It presented as bleeding or spotting per vagina in another 48% of
cases. Epithelioid trophoblastic tumor presented as foul smelling vaginal
discharge.
Asymptomatic  on routine first trimester ultrasound 52(51%)
Bleeding or spotting p/v 49(48%)
Foul smelling  vaginal discharge 1(0.9%)
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GESTATIONAL AGE AT PRESENTATION
Most of the cases (64%) had a history of 2 - 3 months amenorrhea.
Twins (fetus with coexisting mole) presented at 8 months amenorrhea.
Epithelioid trophoblastic tumor had a history of one year of
amenorrhea. 23.2% of patients presented with a history of 4 - 5 months
amenorrhea (Chart 6).
Period of amenorrhea No. of patients %
2months 33 26.4%
3months 47 37.6%
4months 19 14.4%
5months 11 8.8%
8months 1 0.8%
12months 1 0.8%
UTERINE SIZE AT EVACUATION (Chart 7)
In 56% of the cases the uterine size at evacuation was below 14 weeks.
In 37.3% of the cases the uterine size was between 14 to 20 weeks. The
uterine size was between 21 and 28 weeks in 7 cases (6.8%).
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27% of molar pregnancies with uterine sizes more than 20 weeks
developed post molar GTN while 5.3% of the cases with uterine size less than
20 weeks had post molar GTN.
Uterine size No. of patients Percentage
<14 weeks 57 55.9%
14to 20 weeks 38 37.3%
21 to 28 weeks 7 6.8%
UTERINE SIZE IN RELATION TO PERIOD OF AMENORRHEA
In 55.2% of cases, uterus was bigger than the period of amenorrhea
and   7.8% of cases uterus was smaller than the period of amenorrhea. 36.8%
uterus was corresponding to the period of amenorrhea.
Uterine size Number of cases Percentage
Corresponding to GA 42 36.8%
Big(More than GA) 63 55.2%
Small (less than GA) 9 7.8%
Chart7:
UTERINE SIZE AT EVACUATION
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MEDICAL COMPLICATIONS
 Anemia requiring blood transfusion was present in 20 (17.5%) cases.
Fetus with coexistent mole had preeclampsia since 5 months of gestation.
Vomiting requiring anti emetic therapy was present in 21(18%) cases.
Biochemically proven symptomatic thyrotoxicosis was present in 2 (1.6%)
cases. Three (2.4%) patients suffered cough / wheeze during and after
evacuation.
Complications Number of cases Percentage
Anemia          20  17.5%
Vomiting          21  18%
Theca leutin cyst<6cms          9  7.2%
Thyrotoxicosis          2  1.6%
Cough/wheeze          3 2.4%
Preeclampsia          1  0.8%
Ultrasound detected theca leutin cyst (< 6 centimeters) was present in
9(7.2%) cases. 44.4% of patients with bilateral theca leutin cysts developed
post molar GTN after evacuation.
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PRE EVACUATION ? hCG VALUES
? hCG values No. of patients %
> 1 lakh 54 52%
10.000 to1lakh 30 28.8%
1000 to 10,000 20 19.2%
Pre evacuation ? hCG was more than one lakh in 52% of cases and
between 10,000 and one lakh in 28.8% of cases and below 10,000 in 19.2% of
cases. The mean initial ? hCG was 171,915mIU/ml.
11.2% of the molar pregnancies with ? hCG more than one lakh
developed post molar GTN (Chart 8).
TIME TAKEN FOR ? HCG TO NORMALIZE IN NORMAL MOLAR
PREGNANCIES
Weeks  to normal No. of cases Percentage
8 to 12 weeks 50 67.6%
13to 16 weeks 22 29.7%
17 to 20 weeks 2 2.7%
Chart 9:
TIME TAKEN FOR ? hCG TO NORMALISE IN UNEVENTFUL H.MOLE
Chart 10:
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In 67.6% of the uneventful molar pregnancies, it took 8 to 12 weeks
(average of 10 weeks) for the return of ? hCG to normal level (Chart-9).
29.7% cases took an average of 14.5 weeks (13 to 16 weeks) to
normalize. In two patients (2.7%) the average time taken for the ? hCG to
normalize was 18.5 weeks (17 to 20 weeks).
DIAGNOSIS OF GTN
Both the high risk GTN cases after term pregnancy, presented 5-6
months after live birth with metastatic symptoms like breathlessness, cough
and neurological symptoms like headache, giddiness and projectile vomiting.
Both were treated outside for persistent vaginal bleeding after delivery by
check curettage (Chart 10).
Diagnosis of  GTN No. of cases %  of  low risk GTD
Rising value of ? hCG 7 31.8%
Plateauing of ? hCG 6 27.3%
Embolic manifestation 1 4.5%
Persistent bleeding  with uterine disease 2 9%
Histological diagnosis 1 4.5%
Invasive mole(doppler) 5 22.7%
Metastatic symptoms (High risk GTN) 2
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In 31.8% of low risk GTN, the diagnosis was made by rising ? hCG
values. In 27.3% of patients with low risk GTD, there was plateauing of ?
hCG values during follow up.
There were 5 cases (22.7%) of invasive mole diagnosed with doppler
ultrasound. All the five cases were diagnosed during follow up at IOG.
Patient with epithelioid trophoblastic tumor underwent hysterectomy
for profound sepsis and postoperatively diagnosed histopathologically as
ETT.  Immunohistochemistry was done to confirm the diagnosis.
One case presented with breathlessness and cough due to trophoblastic
embolisation during suction evacuation. It was managed with   100% oxygen
ventilation and with bronchodilators.
? hCG REGRESSION CURVE
A log value regression curve was developed from the means and 95%
confidence limits of serial monthly serum ? hCG titers of 72 patients with
uneventful hydatidiform mole and 12 patients who were previously confirmed
as GTN.
All 12 GTN patients (100%) had abnormal values beyond normal
range from the beginning (Chart 11).
50
MEAN AND STANDARD DEVIATION OF SERIAL MONTHLY
?? hCG OF 72 PATIENTS WITH UNEVENTFUL MOLAR PREGNANCIES
Initial 4th week
8th
week
12th
week
16th
week
20th
week
N 72 72 71 60 25 3
Mean 27019.09 2653.113 116.80 4.46 .06 .00
Median 23294.50 500.000 3.90 .00 .00 .00
Std. Deviation 19913.154 5631.4232 414.603 14.218 .187 .000
Minimum 1029 1.3 0 0 0 0
Maximum 91139 36131.0 2658 94 1 0
MEAN AND STANDARD DEVIATION OF SERIAL MONTHLY
? hCG IN 12 PATIENTS WITH PTD
N Minimum Maximum Mean
Std.
Deviation
Initial 12 410.00 471622.00 131448.2 199702.70468
4 weeks 12 56.00 97507.00 17211.43 29131.76072
8 weeks 11 18.00 148339.00 19527.69 46170.273272
10 weeks 9 10.00 50469.00 6093.3289 16660.92304
12 weeks 6 8.00 14782.00 2754.1667 5906.44297
16 weeks 6 2.90 553.00 172.5533 247.62833
Chart 11:
? hCG REGRESSION CURVES IN NORMAL MOLAR PREGNANCIES Vs. GTN
Chart 12:
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WHO SCORES IN GTN
WHO score No of patients Percentage
0 5 22.7%
1 8 36.4%
2 5 22.7%
3 2 9.09%
5 1 4.5%
6 1 4.5%
10(high risk) 1
17(high risk) 1
In 60% of the cases the WHO risk score was 1and 2. In 9% of the cases
the WHO score was 5 and   6. In another 9% of the cases the WHO score was
3. The WHO score was 0 in 22.7% of patients (5 cases).
METASTASIS
Both the high risk GTN cases after full term pregnancy had lung, brain
and vaginal metastasis at presentation.
The high risk GTN case with progressive disease developed spinal
cord metastasis and new brain metastasis while on treatment.
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The lung and vaginal metastasis in both high risk GTN cases
disappeared after treatment with EMA-CO.
Both the high risk cases received cranial irradiation (3000cGY) in 10
fractions for brain metastasis
Site of metastasis Number of  cases
Lung metastasis 2
Brain metastasis 2
Spine metastasis 1
Vaginal metastasis 2
High risk GTN (metastatic) case-1
? 20 year old , para 1, live 1, presented 5 months after child birth by  full
term vaginal delivery  at arakkonam GH with  complaints of  persistent
bleeding per vagina since delivery, headache, giddiness, projectile
vomiting.
? Check curettage was done outside for retained placental bits 2 months
after delivery and the histopathology report was inconclusive.
? CT Brain and Chest x- ray showed multiple brain and lung metastasis.
? Her initial ? hCG was 1648 mIU/ml.
? Her WHO risk score was 10.
Figure  - 16
MRI  of Lumbosacral Spine showing hemorrhagic  intradural metastasis
Figure  - 17
Vaginal metastasis in GTN
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? She was treated with 7 cycles of EMA-CO, 3 cycles of intrathecal
methotrexate 12.5mg and high dose methotrexate (1g) twice.
? She was treated with 3000cGy of brain irradiation in 10 fractions.
?  While on treatment, MRI Spine was taken because of severe back pain
which showed intradural hemorrhagic metastasis at L1-L2.
? She received 10 fractions of lumbar spine irradiation and salvage
chemotherapy (3 cycles) with cisplatin and paclitaxol.
? She developed paraparesis with bladder incontinence due to spinal
metastasis.
? She expired 14 months after diagnosis due to progressive disease.
High risk GTN (metastatic) case-2
?  26 years old, para1live 1abortion1 presented at 6 months after child
birth by full term LSCS at KGH presented with complaints of
breathlessness and persistent bleeding per vagina since delivery.
? Check curettage was done in a private hospital 3 months after delivery
for retained bits of placenta. The histopathology report showed
endometrial glands in proliferative phase with no evidence of chorioic
villi.
? Her initial ? hCG was 2, 25,000 mIU/ml.
? She had sub uretheral nodules and vaginal metastasis.
? Chest X-ray and CT brain showed multiple hemorrhagic metastases.
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? The WHO Score was 17.
? She was treated with 4 cycles of EMA-CO, 3 cycles of PEB, 7 cycles
           of VIP, and salvage chemotherapy with cisplatin and
           cyclophosphamide.
? She received 10 fractions of cranial irradiation (3000 cGys).
? Her CT brain taken after treatment was normal.
? Now her   serum ? hCG values are undetectable. She is on follow up
Epithelioid trophoblastic tumor
? 28 year old, para 1,live1 ,abortion1, with last child birth 10 years back,
presented with complaints of one year of amenorrhea and foul smelling
discharge per vagina for 6 months.
? Her general condition was poor.
? The uterus was irregularly enlarged to 24 weeks.
? Her initial ? hCG was 50,938.
? Ultrasound   revealed a mass in uterus with multiple air pockets.
? Her Chest x-ray was normal.
? Total abdominal   hysterectomy was done for profound sepsis.
? The gross appearance of the uterus specimen revealed a mass in uterus
with extensive necrosis and turbid fluid.
Figure – 15
MRI Brain showing hemorrhagic metastasis in high risk GTN
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? The histopathology report was suggestive of epithelioid trophoblastic
tumor.
? Immunohistochemistry  done  showed  cytokeratin 7+ ve ,
  Ki 67 -10-15%, P63- 70-80%.
? Her WHO risk score was 5.
? She was treated with 10 doses of weekly intramuscular methotrexate .
? Her general condition improved after treatment.
? Her ? hCG values are undetectable for the past 9 months.
GESTATIONAL TROPHOBLASTIC NEOPLASIA (24 CASES)
TREATED AT IOG
GTN following
IOG
(12)
Referral
(12)
Total
Complete Mole 10 7 17(77.3%)
Partial Mole 1 2 3(13.6%)
Epithelioid tumor  after
live birth
1 - 1(4.5%)
Following abortion - 1 1(4.5%)
High Risk GTN(metastatic) -
2(following term
pregnancy)
2
Figure  - 6
Doppler of the vessels shows the invasion of the thin uterine wall
Figure – 7
Gross appearance of Invasive mole, hemorrhagic mass in the myometrial wall
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Invasive mole at IOG             5
         1,   Following Complete mole             4
         2,   Following Partial mole             1
Invasive mole constitutes 4.9% of the total molar pregnancies at IOG
and 41.7% of low risk GTN cases at IOG.
They constitute 22.7% of total treated GTN cases and no cases of
invasive mole was referred from outside.
CHEMOTHERAPY FOR 24 GTN CASES
Single agent  weekly methotrexate 21
Direct EMA-CO for low risk GTN 1
EMA-CO for high risk GTN 2
Resistant to weekly methotrexate 10  low risk GTN
Second line actinomycin D every 2 weeks 7
Second line EMA-CO 3
Third line   PEB  for actinomycin D resistance 1
Of the 22 low risk GTN cases, single agent weekly intramuscular
methotrexate 50mg was given for 21 patients and direct multi agent
chemotherapy EMA-CO was given for one  low risk GTN patient who had a
57
distinct vascularisation  of uterus in doppler . The mean numbers of
chemotherapy cycles given were 8.5 (Chart 12).
Of the 21 methotrexate treated patients, 11 patients (52.3%) achieved
complete remission with methotrexate.
Of the 10 methotrexate resistant low risk GTN cases, 7 patients
received second line chemotherapy with actinomycin D   every two weeks.
Out of the 7 patients treated, 6 (85.7%) patients   achieved complete remission
with actinomycinD.
Second line EMA-CO was given to 3 patients with methotrexate
resistance and all three patients responded to it.
Third line PEB regimen was given for a case with actinomycin
resistance and the patient got cured of disease.
All patients who had undergone repeat curettage for uterine disease
and three of the invasive mole did not respond to first line single agent
methotrexate.
Two repeat molar pregnancy cases who developed GTN did not
respond to single agent methotrexate.
Drug toxicities like oral ulcers and mucositis were present in 33% (8
patients) of treated low risk GTN patients and gastrointestinal disturbances
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like vomiting and diarrhea were reported in 16.6% (4 patients) of low risk
GTN patients.
Three (12.5%) low risk GTN patients had alopecia. Both the high risk
GTN patients had alopecia, gastrointestinal disturbances, oral ulcers and
myelosuppression, and both were treated with filgrastim.
All drug toxicities were grade 1 or 2.
Both the high risk GTN cases did not achieve complete remission with
EMA-CO regimen and were given platinum based regimens.
ASSOCIATED CONDITIONS
Associated conditions Number of  patients
? ANA +ve  nephropathy 1
? AION of right eye 1
? Rheumatic heart disease 4
?  HbsAg +ve 1
? HIV + ve 1
? Bicornuate uterus 2
We had 3 cases of rheumatic heart disease complicating molar
pregnancies.
59
There were two cases of bicornuate uterus with molar pregnancy.
Ultrasound guided suction evacuation was done in both the cases.
Three cases of atypical placental site nodules were registered for
follow up. All the 3 cases spontaneously expelled the dead fetus at 6-7 months
of gestation and placenta along with a solid mass and were
histopathologically diagnosed as benign chorioangioma.
OUT COME
Outcome Number of cases
Completed follow up 4
Pregnancy during follow up 4
On follow up 88
Defaulters 16(15.6%)
On Chemotherapy 1
Expired high risk GTN 1
Quiescent GTD 1
At a mean follow up of 18 months, 4 patients had completed follow up.
Four patients were non compliant with the contraceptive measures and
became pregnant during follow up.
16 patients (15.6%) were lost to follow up including one low risk
GTN.
60
One low risk GTN patient is on chemotherapy.
90 patients are on regular follow up which includes 21 cases of low
risk GTN cases (95.5%low risk GTDs), one case of high risk GTN and 66
benign molar pregnancies (73.3% of normal molar pregnancies).
One patient had persistent low levels of ? hCG (Quiescent disease).She
was thoroughly investigated for occult disease and is being closely followed
up.
One patient died of progressive high risk metastatic disease due to late
presentation in advanced disease, 14 months after the diagnosis.
One patient with low risk GTN on chemotherapy defaulted as her
husband got transferred to Bangalore and is advised treatment there.
One patient (3rd gravida with two live children) underwent sterilization
6 weeks after molar evacuation.
DISCUSSION
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The incidence of molar pregnancies at IOG is 5 per 1000 pregnancies.
The reported incidence of GTD varies worldwide from a low of 0.23/1000 in
Paraguay to a high of 12.99/1000 in Indonesia (Alteiri A et al) 56.
The incidence of hydatidiform mole is 5.3 per 1000 deliveries   in a 15
year study done at the Calicut Medical College (Shekheran P K et al) 15.
In a study from Pakistan by Marukh Fatima et al in 201158, the
incidence of molar pregnancies is 5.1 per 1000 pregnancies.
In a survey conducted in China including 143 hospitals, the incidence
of GTD was 3.87 /1000 pregnancies. (Shi YF et al et al).57.
The hospital based incidence   reported from certain teaching hospitals
in India shows an incidence of 1 in 150 to 1 in 300 deliveries (Shekheran PK
et al) 15.
A study, by Smith HO et al, there is a relationship between ethnicity
and risk of molar pregnancy and incidence is highest in American Indians,
Eskimos and Asian population.59
This increased incidence in Asians is due to unfavorable socio
economic and nutritional factors.
Of the 102 IOG cases, 80 cases (78.4%) were complete mole, 21cases
(20.5%) were partial mole and one (0.9%) was a case of ETT. 4.9% of the
total GTD cases at IOG were invasive mole.
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In our study, most cases (81%) presented between 20- 29 years which
is the peak fertility group (mean24.5 years).
In the Chinese Survey of GTD among 3.6 million pregnancies, the
GTD cases mainly occurred among 20-34 year old women.57
 In a study by Soares PD et al, GTD predominated in the peak fertility
age group (20-34 years) and among patients of unfavorable socioeconomic
status.60
The risk associated with maternal age is bimodal with increased risk
for both   less than 20 years and more than 35 years. The relative risks are in
the range of 1.1 to 11 (Altman AD et al 2008). 61
In our institution, most of the cases (64%) had a history of   2 and 3
months amenorrhea.
In 56% of the cases the uterine size at evacuation was below 14 weeks.
In 37.3% of the cases the uterine size was between 14 to 20 weeks and the
uterine size was between 21 and 28 weeks in 7 cases (6.8%).
 In our institution, 27% of the patients with uterine size 20 weeks or
more developed post molar GTN. In uterine sizes more than 24 weeks at
evacuation, one third of the patients developed post molar GTN.
25% of patients with large for dates uterus developed GTN compared
to 11% of patients with small for dated uterus (Berkowitz RS et al) 9.
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Soto Wright et al demonstrated a reduction in the mean gestation at
presentation from 16 weeks in 1970s to 12 weeks in 1990s.62
In our study, 51% cases of molar pregnancy were diagnosed in routine
early first trimester ultrasound in asymptomatic women with history of
amenorrhea. Patients with GTD presented as bleeding or spotting per vagina
in another 48% of cases.
 Routine pre-evacuation ultrasound examination identifies less than
50% of hydatidiform mole, the majority sonographically appearing as missed
miscarriage or blighted ovum. Detection rates are, however, higher for
complete compared to partial mole, and improve after 14 weeks' gestation.
Histopathological examination of products of conception remains the
current gold standard for the identification of gestational trophoblastic
diseases (Fowler DJ et al 2006).30
The use of serum ? hCG as a screening tool to identify those women
with anembroyonic pregnancies would enable us to counsel women more
confidently towards non-surgical methods of management if the ? hCG is
low. It would also provide us with a useful follow-up tool for those cases in
which histopathological assessment is not possible (John J et al) .29
At our institution, 17.5% of patients had anemia and 18%of cases had
vomiting requiring antiemetic treatment. Only 2 cases (1.6%) had features of
hyperthyroidism and one patient (0.8%) had preeclampsia. Respiratory
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symptoms were present in 2.4% cases and sonographicaly detected theca
leutin cysts (less than 6 centimeters) in 7.2% of cases.
 Nowadays, fewer patients with complete hydatidiform mole present
with the traditional symptoms of complete hydatidiform mole (excessive
uterine size, anemia, preeclampsia, hyperthyroidism, or hyperemesis).
However, there has been no statistically significant change in the
development of persistent gestational trophoblastic tumor in current patients
(Hou J L et al).31
 In our study, a log value regression curve was developed from the
means of serial monthly serum ? hCG titers of 72 cases of normal uneventful
molar pregnancies and 12 low risk GTN cases.
A normal regression curve may help the physician to decide on a single
random value and to change the intervals of follow up visits in selected
patients.
It may also facilitate the earlier recognition of GTN, than the plateau or
rise of level of ? hCG (Behtash N et al).48
In our study, in 97.3% of normal molar pregnancies, the serum ? hCG
reached normal values in 8 to 16 weeks.
Several authors have described serum ? hCG concentrations to be
normalized in 50% of patients between 6 and 14 weeks after evacuation.
(Behtash N et al).48
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Approximately 50% of patients with complete mole have pre
evacuation ? hCG levels 100,000 mIU/mL (Lurain JR et al).7
At our institution, pre evacuation ? hCG was more than one lakh in
52% of cases and between 10,000 and one lakh in 28.8% of cases.
We had a case of twin gestation with complete molar pregnancy. She
was diagnosed during routine ultrasound at 6 months amenorrhea. Ultrasound
showed diamniotic dichorionic twin pregnancy, one sac showing structurally
normal fetus (24 weeks) with normal placenta and another sac showing a
complete mole (20*10*9cms).Her initial ? hCG was 24,888mIU/ml.
She developed pre-eclampsia at 26 weeks and was treated with
antihypertensives. At 30 weeks of gestation, patient spontaneously delivered a
live boy baby (720grams) with good apgar. Baby died 5 days after birth due
to extreme prematurity and hyaline membrane disease. About 2 kg of cystic
vesicular tissue was evacuated from the uterus with normal placenta after
delivery of the baby. Her ? hCG values became undetectable by 8 weeks after
delivery.
Complete mole and co-twin pregnancies have a high risk of
spontaneous abortion, but about 40% result in live births, without
significantly increasing the risk of GTN (Sebire NJ et al).65
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Evidence comparing early versus delayed evacuation of molar
pregnancy suggest that delayed termination has no increased risk of malignant
disease (Seckl MJ et al) 66.
This suggests that molar pregnancies are probably preprogrammed to
behave malignantly at an early stage of development before uterine
evacuation.
So, oxytocin infusion during evacuation helps to minimize bleeding
without increased risk of persistent disease (Shekheran PK et al) 3. An
oxytocin infusion may be started before induction of anesthesia to facilitate
contraction and thus decrease blood loss.
Concern has been expressed that oxytocin may promote metastasis of
trophoblastic tissue. However, it has been reported that uterine stimulation
during evacuation did not increase the risk of persistent tumor (Shekheran PK
et al) 13.
In our institution, we ripen the cervix with 200mg of misprostol four
hours before molar evacuation and start oxytocin infusion at the beginning of
evacuation.
We had four cases of repeat molar pregnancies constituting 3.5%of the
total molar pregnancies. In one case, it was the fourth repeat molar pregnancy.
It was the third molar pregnancy in two cases and the second molar pregnancy
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in one case .Only the case with two molar pregnancies had a live birth before
the mole
3 out of the 4 (75%) repeat molar pregnancies developed post molar
GTN.
Women having a pregnancy affected by a histologically confirmed
complete or partial hydatidiform mole may be counseled that the risk of
repeat mole in a subsequent pregnancy is about 1 in 80 and the risk after two
previous molar pregnancies is 1:6.5.
If this repeat mole is to occur, the majority of cases will be of the same
type of mole as the preceding pregnancy.
However, >98% of women who become pregnant following a molar
conception will not have a further hydatidiform mole and these pregnancies
are at no increased risk of other obstetric complications (Sebire NJ et al)65.
        15.6% of the patients with molar pregnancies were lost to follow up in
our study.
In a study from Al Quetta, Pakistan, 23% of the GTD patients were lost
to follow up.
We counsel the patients and their family regarding the importance of
follow up after evacuation of molar pregnancies and the need for
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contraception throughout the follow up period and regarding their
psychosocial issues.
        Patients are lost to follow up mainly due to illiteracy, change of
residence due to job transfers and social problems regarding the use of
contraception.
The incidence of post molar GTN at our institution is 10.8% of molar
pregnancies.
In a 15 year study from Calicut Medical College by Sekheran et al, the
incidence of post molar GTN was 20.5%.15
A total of 22 low risk GTN cases and 2   high risk metastatic GTN
cases were treated at IOG. Both the high risk GTN cases were referral cases
after term pregnancy and presented with metastatic symptoms.
The incidence of persistent GTN after a live birth is estimated at 1 in
50,000 live births (Smith HO et al 2003).64
In our study, the antecedent pregnancy was hydatidiform mole in 20
cases (83.3%) of low risk GTN and abortion in one low risk GTN (4.2%).
The antecedent pregnancy was full term pregnancy in 12.5% of cases.
In a study from All India Institute of Medical Sciences, New Delhi, the
antecedent pregnancy was hydatidiform mole in 50% of GTN cases and
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abortion in 34.3% of cases, and ectopic pregnancy in 4% of cases and term
pregnancy in 11.8% of cases.
In our study, low risk GTN is diagnosed in 60% of cases as rising or
plateauing ? hCG values. In 22.7% of cases, invasive mole was diagnosed
using doppler ultrasonography. Two cases had persistent vaginal bleeding
after evacuation. One case had respiratory difficulty during evacuation.
Pulmonary complications at evacuation are caused by trophoblastic
embolization or high output cardiac failure by anemia, hyperthyroidism,
pre-eclamsia or iatrogenic fluid overload. They are treated aggressively by
central hemodynamic monitoring and ventilator support as required
(Soper TJ et al) 4.
In our study, Only ETT had histopathological diagnosis. Immuno
histochemistry showed cytokeratin and p 63positivity.
The term 'epithelioid trophoblastic tumor' was originally introduced by
Mazur and Kurman in 1994. In 1998, Shih and Kurman outlined the
clinicopathologic characteristics of epithelioid trophoblastic tumor in 14
patients, and therefore established epithelioid trophoblastic tumor as a distinct
entity within the category of gestational trophoblastic tumors. Since then,
approximately 90 cases have been reported in the literature.
Histologic features include a nodular growth pattern of monomorphic,
epithelioid cells within a hyaline matrix. Immunohistochemical staining
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revealed strong diffuse reactivity for cytokeratins (CK7, CK18) , HLA-G and
epidermal growth factor receptor, and focal reactivity, mainly in
syncytiotrophoblastic cells, for  ? hCG , hPL and inhibin-?. Currently, we
manage ETT in the same way as PSTT( Olewole F et al)71.
          The patient with quiescent GTD was a case of invasive mole diagnosed
by doppler ultrasonography, treated with 13 cycles of weekly intramuscular
methotrexate .Her ? hCG values were undetectable for 3 months after which it
is persistently low (<100 mIU/ml) for the past eight months. Her urine
pregnancy test is positive. Her ultrasound and doppler of the abdomen and
pelvis, chest x-ray, CT brain   are normal. She is under close follow up.
          Clinicians frequently assume that an elevated  ?  hCG implies that a
patient is pregnant or has GTD or recurrent GTN, even when apart from the
pregnancy test, no clinical evidence was found to support such a diagnosis. In
most of these cases of persistent low ? hCG etiologies, all therapies were
found unnecessary and ineffective.
It is essential to demonstrate a malignancy clinically and with readily
available biochemical tests (? hCG >3000 IU/L) before initiating therapy.
This applies whether the patient is identified by an incidental pregnancy test
or is actively being monitored for gestational trophoblastic disease (Cole LA
et al) 33.
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               In our study, the response rate to weekly intramuscular methotrexate
in low risk GTN was 52.3%.The response rate to second line actinomycin D
every 2 weeks was 85.7%.The response rate to second line EMA-CO was
100%.
In our study, one case with actinomycin D resistance was treated with
PEB regimen.
 In our institute, chemotherapy is continued until ? hCG values have
achieved normal levels, and an additional course is administered after the first
normal ? hCG value has been recorded ( Soper TJ et al ) 4.
The weekly intramuscular methotrexate regimen was as effective as
the 8-day methotrexate-folinic acid regimen every 2 weeks for low-risk GTN.
The weekly methotrexate regimen was less toxic, better tolerated, and more
convenient for patients compared to the 8-day methotrexate-folinic acid
regimen (Kang WD et al).67
 In our study, the cure rate of low risk GTN patients is 100%. Apart
from minor side effects, there were no drug toxicities in low risk GTN
patients.
In a randomized phase 3 trial by the GOG , the response rate was 58%
and 73% in the weekly methotrexate and  actinomycin D arms respectively
(Raymond JO et al 2011).68
In a retrospective  study to examine the efficacy of single agent weekly
intramuscular methotrexate , data support that methotrexate  is the appropriate
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first line therapy for low risk GTN irrespective of patient characteristics like
age, race, metastasis, prior mole and ? hCG values . The primary remission
rate with weekly methotrexate was 54.2%.Failure of methotrexate has no
impact on the eventual remission and patient survival, in patients requiring 2nd
line chemotherapy (Q K Lippmann et al 2011).69
 In our study, both the high risk GTN cases with brain and lung
metastasis did not achieve complete remission with EMA-CO. Both were
given salvage chemotherapy with cisplatin and ifosfamide containing
regimens. One patient died of progressive disease.
Both the patients received cranial irradiation (3000cGy) in 10
fractions. High dose methotrextate (1g/sq.m) and intrathecal methotrexate
(12.5mg) was given to the patient with progressive disease.
 Evidence suggests that clinical complete response to EMA-CO in high
risk GTN cases was influenced by
1,  ? hCG level (<100,000 mIU/ mL, 82%, vs.>100,000   mIU/mL, 46%),
2,  Metastatic site (lung and pelvis, 75%, vs. other, 33%) and
3,  FIGO risk score (<7, 92% vs.>7, 50%).
The overall survival rate was 80-90% in high risk GTN cases with
initial EMA-CO, often in conjunction with brain irradiation, salvage
chemotherapy and surgical resection (Lurain JR et al). 70
SUMMARY
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Since survival is 100%, patients should be first given the least toxic
therapy.
? Due to lack of proper follow up and appropriate treatment, patient
often present late in the disease where the outcome is going to be poor,
hence the need for early referral to a specialized center.
? Patients with malignant GTN should be managed with complex
multimodality treatment.
? A new prognostic test at the time of initial molar diagnosis is needed to
identify   those  who develop malignant disease
? The prognosis and outcome of GTD is exceptionally good if diagnosed
and treated in time with regular follow up primarily at a specialized
center.
? Centralization of treatment would provide the opportunity to build
clinical expertise on GTD, which would further improve outcomes    in
the management of    GTN.
? The emotional, psychological, and social impact of the diagnosis of
GTN on the patient and family should be addressed by counseling.
This approach will ensure optimal holistic care for women with GTN.
CONCLUSION
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? The incidence of   gestational trophoblastic diseases had decreased
over the past decade worldwide due to fall in birth rates and improved
socioeconomic status.
? In considering clinical presentation, most patients are asymptomatic
and are diagnosed during routine first trimester ultrasound.
? The ultrasound detection rate of molar pregnancy in first trimester is
56% and is imaged as blighted ovum or missed miscarriage. Hence the
need for histopathological examination of products of conception in all
anembryonic pregnancies.
? Serum ? hCG is done in early pregnancy failures if there is a high
suspicion of molar pregnancy. Otherwise urine pregnancy test at 4
weeks after termination is done in cases of early pregnancy failures
where products of conception are not send for histopathology.
? Low risk GTN cases are 100% curable. There is no case of high risk
disease at our institution .The patients are counseled on the need for
follow up and contraception.
? Weekly intramuscular methotrexate regimen is highly effective in
curing low risk GTN cases. Methotrexate is less toxic, inexpensive,
and convenient to use and there is no need for hospitalization and
patient compliance is better with the weekly methotrexate regimen.
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? The incidence of molar pregnancies is 5 per 1000 pregnancies at IOG,
as our institution is a tertiary referral center.
? The incidence of post molar GTN at IOG is 10.8% of molar
pregnancies.
? All post molar low risk GTN cases are effectively treated with single
agent weekly methotrexate, the failure of which is easily salvaged by
second line monotherapy with actinomycin D.
? All low risk GTN cases are 100% curable. Overall survival is 100%
? There is a need for centralization of care   with a regional registry and a
central pathology review.
? It is important to manage molar pregnancies properly in specialized
centers to minimize acute complications and identify malignant
sequelae promptly.
? Follow up plays a major role to decrease morbidity associated with
molar pregnancies.
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ANNEXURES
PROFORMA
1.  Name                      Age             IP No
      Address & Phone No.
 2.   Clinical Presentation
- Gravida      Para    live births      abortions
- months of  amenorrhea
-  Bleeding p/v
- Detected without any complaint on ultrasound
 3.   Associated Complaints  -anaemia
- Hyperemesis
- Hypertension
- Thyroid Symptoms
- Embolic symptoms
- metastatic symptoms
 4  Gestational Age at the time of Diagnosis
- Uterine size in relation with gestational age
5.   Menstrual History
           Menarche  Cycles Flow LMP
 6.   Obstetric History
 -  Gravida     Para     Live births      Abortions
 - previous molar pregnancy
- h/o contraceptive use
7. Past Medical History
8. Family History
           - h/o  molar pregnancies in other  wives of husband
 9. Personal History
10. General Examination
height               weight                 BMI
pallor              hydration status   icterus
Pulse rate                              BP
PS                                          BSA
11. Physical Examination
           Cardio vascular  and Respiratory system
            Abdominal examination before and after evacuation
           uterine size
           Theca leutin cysts and size
          Bimanual pelvic examination
12. Investigations
? Serum ß HCG
? Ultrasound  abdomen and pelvis and doppler if required
? Chest X-ray
?  Complete hemogram
? Blood grouping and typing
?  Renal and liver function tests
? Thyroid function tests
? CT Brain ,abdomen if required
13. Evacuation   Details
14. Histopathology Report
15. Chemotherapy Details (if given)
16. Follow Up
ABBREVIATIONS
GTD - Gestational Trophoblastic diseases
CM  - Complete mole
PM  - Partial mole
CC - choriocarcinoma
PSTT  - Placental site trophoblastic tumor
ETT  - Epithelioid trophoblastic tumor
GTN - Gestational trophoblastic neoplasia
?hcg - human chorionic gonadotrophin
hPL - human placental lactogen
mIU/ml – milli international units/milliliter
IT - intermediate trophoblast
IU/L - international units/liter
LH  - Luteinizing hormone
FIGO - International Federation of Gynecology and
Obstetrics
WHO  – World Health Organisation
CT - Computed Tomography
MRI - magnetic resonance imaging
FDG PET -2,  - fluro deoxy glucose positron emission
tomography
PTD – Persistent trophoblastic tumor
Cms - Centimeters
RCOG –  Royal College of Obstetrics and Gynecology
GTG - Green top guidelines
ACOG - American College of Obstetrics and
Gynecologists
GOG - Gynecology Oncology Group
NETDC – New England Trophoblastic Disease Center
OCP –  Oral Contraceptive Pills
SPSS -  Statistical Programme for Social Sciences
mg -  milligram
EMA-CO – Etoposide ,  Methotrexate ,  Actinomycin ,
Cyclophosphamide , Oncovin
EMA –EP -  Etoposide , Methoterxate , Actinomycin ,
Etoposide , Cisplatin
VIP - Vinblastin , Ifosfamide , Cisplatin
ICE  - Ifosfamide , Carboplatin , Etoposide
TE/TP – Paclitxol , Etoposide , Cisplatin
PEB - Cisplatin , Etoposide, Bleomycin
RR - Relative Risk
IOG - Institute of Obstetrics and Gynecology
KMC – Kilpauk medical College
ISO KGH – Institute of Social Obstetrics , Kasturibai Gandhi
Hospital
SMC  – Stanley medical college
GH  - Government Hospital
GA -  Gestational age
cGY  – centiGray
g  -  grams
sq.m - square meter
HLA - human leucocyte antigen
ANA – Antinuclear antibody
AION  – Anterior ischemic optic neuropathy
HIV – Human Immunodeficiency Virus
HbS Ag+ve    - Hepatitis B surface antigen positive
AML – Acute myeloid leukemia
UK - United kingdom
INFORMED CONSENT
PART 1
STUDY TITLE:  “Prospective study of natural history, follow up, treatment
and outcome of patients with Gestational trophoblastic
disease attending IOG”.
STUDY CENTRE: Department  of  Obstetrics  and  Gynecology,  Institute  of
Obstetrics and Gynecology, Egmore, Chennai- 8.
PARTICIPATE NAME:   AGE ADDRESS: IP/ OP NO:
INFORMATION SHEET
Gestational trophoblastic disease includes molar pregnancies and related
disorders  which  are  due  to  abnormal  fertilization  of  egg,  with  no  formation  of  the
baby and results in multiplication of placenta forming trophoblastic cells.
Suction  evacuation  is  the  treatment  after  initial  evaluation  with  blood  tests,
chest xray and ultrasound. Since there is a risk of malignant disease after evacuation,
all  patients  with  molar  pregnancies  after  evacuation  are  followed up  with  serum ?
hcg at regular intervals. It is necessary to use contraception (oral contraceptive pills
or codomn) in the follow up period.
If malignancy is detected in the follow up period, it is completely curable
with chemotherapy regimens and future fertility is well preserved.
All patients will be treated according to hospital guidelines and protocols.
The study is being performed for the estimation of incidence, natural history,
treatment, follow up and outcome of patients with gestational trophoblastic disease
attending IOG.
PART 2
I confirm that I have read and understood the Information Sheet for the
above study and the purpose of the above study. I have the opportunity to ask the
question and all my questions and doubts have been answered to my satisfaction.
I have been explained about the study details. I understand that my
participation  in  the  study  is  voluntary  and  that  I  am  free  to  withdraw  at  any  time
without giving any reason.
I understand that investigator, regulatory authorities and the ethics committee
will not need my permission to look at my health records both in respect to the
current study and any further research that may be conducted in relation to it, even if
I withdraw from the study. I understand that my identity will not be revealed in any
information released to third parties of published, unless as required under the law. I
agree not to restrict the use of any or results that arise from the study.
I hereby give permission to undergo complete clinical examination
diagnostic tests including hematological, biochemical, and radiological tests.
 I have been informed that I will be given treatment according to the cause as
per the hospital guidelines
I hereby consent to participate in this study of Prospective study of natural
history, follow up, treatment and outcome patients with Gestational trophoblastic
disease attending IOG.
Signature / Thumb impression of patient                      Place                                  Date
Name and Signature of witness                                     Place                                 Date
Study Investigators Name
Signature of Investigator                                                 Place                              Date
Institution:
Guide
      Ra xg;g[jy; gotk;
Ma;t[ bra;ag;gLk; jiyg;g[ : Kj;Jg;gps;is nehapd; tpfpjk; ,ay;g[
jd;ik rpfpr;ir Kiw bjhlh;
fz;fhzpg;g[ kw;Wk; rpfpr;ir gyd; gw;wpa
vjph;nehf;F Ma;t[
Ma;t[ bra;ag;gLk; ,lk; : muR kfg;ngW kUj;Jtkid. vGk;g{h;.
brd;id/
Ma;tpy; g';F bgWgthpd; bgah; : taJ  nehahsp vz;
Kfthp
gFjp ? 1 nehahspapd; jfty; gotk;
Gestational Trophoblastic Disease vd;gJ Kj;Jgps;is kw;Wk; mjd; rhh;e;j
neha;fs; cs;sl';fpaJ/ Kj;J gps;is neha; rhpahd Kiwapy;
fUj;jhpf;fhjjhy;. FHe;ijfs; cWg;g[fs; cUthfhky; e";Rf; bfho jpRf;fs;
kl;Lk; mjpfkhf tsUk; xU neha;/
,jw;F ,uj;jg;ghpnrhjid. !;nfd;. khh;g[g; gFjp vf;!;nu
ghpnrhjidfis bra;j gpwF cwp";R FHha; K:yk; Kj;Jgps;isia btspna
mfw;Wtnj ,jw;Fhpa rpfpr;irahFk;/
Kj;Jgps;is neha; te;j rpyUf;F mJ g[w;W nehahf khWtjw;fhd
tha;g;g[ cs;sJ/ ,jdhy; bjhlh; fz;fhzpg;g[ rpfpr;ir kpft[k; mtrpak;/ cly;
ghpnrhjid ?hcg ,af;FePh; ghpnrhjid. !;nfd; Mfpatw;iw rhpahd
,ilbtspapy; njitahd bghGJ bra;J bfhz;lhy; g[w;W nehia Muk;g
epiyapnyna fz;lwpe;J tplyhk;/
,e;j g[w;Wneha;f;F kUe;Jfs; K:yk; vspjhf rpfpr;ir bra;J KGjhf
Fzkila tha;g;g[ cs;sJ/ bjhlh; fz;fhzpg;g[ rpfpr;ir bra;a[k;nghJ khjhe;jpu
fUj;jil khj;jpiufs; my;yJ MQqiw Mfpa fUj;jil Kiwfis
cgnahfpg;gJ mtrpak;/ rpfpr;ir Koe;j gpd; fUj;jUg;gjpnyh. FHe;ij
bgWtjpnyh vt;tpj gpur;rpida[k; Vw;glhJ/,k;kUj;Jtkidapd; tpjpfSf;Fl;gl;L
Kj;Jgps;is neha;f;fhd rpfpr;ir mspf;fg;gLk;/
,e;j vjph;nehf;F Ma;t[ Kj;Jgps;isapd; nehapd; tpfpjk;. ,ay;g[..
jd;ik. rpfpr;ir Kiw bjhlh;fz;fhzpg;g[ kw;Wk; rpfpr;ir gyd; mwptjw;fhf
nkw;bfhs;sg;gLfpwJ/ ,e;j Ma;tpdhy; vt;tpj ghjpg;g[k; ,y;iy/
gFjp ?2
 vdf;F Kj;Jg;gps;is neha; gw;wp vLj;Jf; Twg;gl;lJ/ mjd; rpfpr;ir
Kiwfis gw;wp tpsf;fk; mspf;fg;gl;lJ/ vd;Dila re;njf';fis nfl;ft[k;.
mjw;fhd jFe;j tpsf;f';fis bgwt[k; tha;g;gspf;fg;gl;lJ.
 ehd; ,t;tha;g;gpy; jd;dpr;irahfj;jhd; g';nfw;fpnwd;/ ve;j
fhuzj;jpdhnyh ve;j fl;lj;jpYk; ve;j rl;l rpf;fYf;Fk; cl;glhky; ehd;
,t;tha;tpy; ,Ue;J tpyfp bfhs;syhk; vd;Wk; mwpe;J bfhz;nld;/
 ,e;j Ma;t[ rk;ke;jkhfnth. ,ij rhh;e;j nkYk; Ma;t[ nkw;bfhs;Sk;
nghJk; ,e;j Ma;tpy; g';F bgWk; kUj;Jth; vd;Dila kUj;Jt
mwpf;iffis ghh;g;gjw;F vd; mDkjp njitapy;iy vd mwpe;J bfhs;fpnwd;/
ehd; Ma;tpy; ,Ue;J tpyfp bfhz;lhYk; ,J bghUe;Jk;/ vd mwpfpnwd;/
 ,e;j Ma;tpd; K:yk; fpilf;Fk; jfty;fisa[k;. ghpnrhjid Kot[fis
kw;Wk; rpfpr;ir bjhlh;ghd jfty;fisa[k; kUj;Jth; nkw;bfhs;Sk; Ma;tpy;
gad;gLj;;jpf; bfhs;st[k; mij gpuRhpf;ft[k; vd; KGkdJld; rk;kjpf;fpnwd;/
 ,e;j Ma;tpy; g';F bfhs;s xg;g[f;bfhs;fpnwd;/ vdf;F bfhLf;fg;gl;l
mwpt[iufspd;go ele;J bfhs;tJld; ,e;j Ma;it nkw;bfhs;Sk; kUj;Jt
mzpf;F cz;ika[ld; ,Ug;ngd; vd;Wk; cWjpapspf;fpnwd;/ vd; cly; eyk;
ghjpf;fg;gl;lhnyh my;yJ vjph;ghuhj tHf;fj;jpw;F khwhd neha;f;Fwp
bjd;gl;lhnyh clnd mij kUj;Jt mzpaplk; bjhptpg;ngd; vd cWjp
mspf;fpnwd;/
 ,e;j Ma;tpy; vdf;F ,uj;jk;. !;nfd;. vf;!;nu ghpnrhjid bra;J
bfhs;s ehd; KG kdJld; rk;kjpf;fpnwd;/
g';nfw;gthpd; ifbahg;gk; - fl;il tpuy; nuif //////////// ,lk; /////////////////// njjp
rhl;rpahshpd; bgah;. ifbahg;gk; //////////// ,lk; /////////////////// njjp
Ma;thshpd; bgah;. ifbahg;gk//////////// ,lk; /////////////////// njjp
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1 112/10 23 G3P2L2 USG cough      anemia 3MA 12 CM, B/L TLC N 471,622 19 CM GTN 0 SE/MTX11 ND 1 year IOG
2 115/10 19 primi Bleeding                - 3 MA 18 CM N 299463 16 CM         -            -                          SE ND 6mon IOG
3 116/10 19 primi USG                - 3MA 20 CM N 217653 11 CM                -            - SE ND   4 mon IOG
4 118/10 27 G2P1L1 Spotting vomiting 4MA 12 PM N 41000 31 PM GTN 1 SE/MTX4/   Act2 ND 10 mon KGH
5 119/10 20
P1L1
(FTND) Bleeding
Giddiness, headache,
vomitting FTND 12 ? Retained  POC mets 16480                -        - high risk GTN 10 EMACO,RT expired Arakkonam GH
6 126/10 23 G2P1L1 Missed abortion AION of right eye 3MA 18 Retained POC N 15530 8 - GTN 1 SE/MTX7/    Act2
ND 6mon,
pregnant SMC
7 130/10 20 G2P1L1 USG vomiting ,    anemia 3MA 12 CM N 225000 16 CM                        - - SE ND 10 mon IOG
8 131/10 29 G3P2L1 USG                                  - 3MA 12 CM N 225000 24 CM GTN 1 SE/ MTX3/    Act5 ND 9 mon IOG
9 132/10 26 G3P2L1 USG
Spotting after SE, cough
wheeze 3MA 12 CM N 18110 12 CM GTN 1 SE/MTX8 ND 1year KGH
10 133/10 25 G3P1L1A1 Bleeding anemia 3MA 18 CM, BL - TLC N 1430 12 CM                 -                - SE ND 3 mon IOG
11 135/10 25 G3P1L1A1 Foul smelling discharge LCB - 10 yrs 12 MA 24
Multiple Air
pockets in Ut. N 50938 32 ETT GTN 5 TAH/MTX10
ND  3 mon
pregnant IOG
12 137/10 21 G2A1 Spotting anemia 3 MA 16 CM N 500000 19 CM GTN 6 SE/MTX10 ND 11 mon Pvt
13 139/10 19 primi Bleeding vomiting 5MA 20 CM N 140000         - C. mole                    -              - SE defaulter IOG
14 143/10 27 G2P1L1
USG  DCDA twins  fetus
with  CM anemia ,PIH 8MA 28 fetus with CM N 24888 8 CM            -             - LN/ SE ND 10 mon IOG
15 145/10 25 G3P2L2 Bleeding rpt SE 3MA 20 PM N 13409              - PM -              - SE Defaulter IOG
16 146/10 21 primi Spotting                             - 3MA 20 CM N 200000               - CM                       - `            - ` SE Defaulter IOG
17 148/10 32 G2P1L1 Bleeding Invasive mole 2MA 16 PM N 55440 24 PM GTN 2 SE/MTX9/  Act5 ND 10 mon IOG
18 149/10 18 primi Spotting vomiting,    anemia 3MA 16 PM N 3350 8 PM                       -            - SE ND 1year IOG
19 151/10 25 G3P2L2 Bleeding                       -  4MA 20 CM N 139108 17 CM                 -            - SE ND 10 mon IOG
20 152/10 20 primi USG                         - 2MA 10 PM N 3767 8 PM                      -            -  SE
ND 5 mon
pregnant IOG
21 156/10 33 G2P1L1 Bleeding anemia 2MA 24 CM N 150000                - CM                      -           - SE Defaulter IOG
22 160/10 22 G2P1L1 Bleeding                            - 2MA 12 CM N 39882 8 CM                   -            - SE ND 1year IOG
23 169/10 21 primi Bleeding                          - 3MA 16 CM N 10290 8 CM                    -                 - SE ND 1 year IOG
24 170/10 24 G2P1L1 Bleeding  Bleeding, invasive mole 2MA 10 CM N 35,509 28 CM GTN 2 SE/MTX11/    Act2 Quiescent disease IOG
25 171/10 23 G3P2L2 spotting               - 5 MA 18 CM N 172966 12 CM   -     - SE Defaulter IOG
26 176/10 25 G2P1L1 spotting anemia 3 MA 16 CM N         4,69,525 16 CM   -   - SE ND 8 mon IOG
27 177/10 22 primi spotting vomiting , 3 MA 12 CM N 413862 16 CM   -     - SE ND 8 mon IOG
28 180/10 23 G3A2 spotting vomiting     repeat mole 3MA 12 CM N 12900 28 CM GTN 3
SE/MTX6/   Act4
PEB4 ND 9mon IOG
29 181/10 17 primi bleeding
vomiting    cough
anemia 3MA 24 CM N 431088   - CM   -   - SE  defaulter IOG
30 187/10 21 primi Bleeding   - 3MA 16 CM N 97,346 12 CM   -    - SE ND 10 mon IOG
31 188/10 27 G3P1L1A1 Bleeding    - 2MA 10 PM N 3124 8 PM    -    - SE ND 10 mon IOG
32 191/10 18 primi USG    - 4MA 20 CM N        5,00,000    -   CM    -    - SE  defaulter IOG
33 192/10 30 G2P1L1 USG anemia,RHD 2MA 16 PM N        1,81,847 8 PM   -    - SE ND 11  mon IOG
34 200/10 22 primi bleeding BA 2MA 10 CM N 2,25,000 16 CM   -   - SE ND 9 mon IOG
35 202/10 23 G2P1L1 spotting    - 3 MA 16 PM N 3078 16 PM   -   - SE ND 9 mon IOG
36 204/10 19 primi bleeding    -  4MA 16 CM N 3,27,364    - CM   -    - SE   Defaulter IOG
37 207/10 32 G3P2L2 USG vomiting 3MA 12 PM N 37155 12 PM   -   - SE ND 10 mon IOG
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38 210/10 23 G2P1L1 USG Anaemia 4MA 16 CM/TLC(B/L) N 6245   - CM   -    - SE    defaulter IOG
39 214/10 23 primi USG    - 4MA 16 CM N 1,13,657   - CM   -    - SE  defaulter IOG
40 219/10 26
P1L1A1
(FTLSCS) bleeding, breathlessness vaginal nodule FTLSCS 10 ?retained POC mets 2,25,000 40   - high risk GTN 17 EMACO , RT ND 3 mon KGH
41 220/10 21 primi USG vomiting 3MA 12 CM N 118175 9 CM   -   - SE ND 6 mon IOG
42 223/10 23 G2P1L1 USG Anemia,     bicornuate ut 3MA 12 CMin both horns N 2,25,000 12 CM   -   - SE ND 8  mon IOG
43 226/10 25 G3P2L2 USG RHD 5MA 20 CM N 11582 10 CM   -   -
SE and  intervel
TAT ND 6 mon IOG
44 236/10 24 G4P3L2 bleeding    - 3MA 16 PM N 35,220 16 PM    -   - SE ND 6 mon IOG
45 238/10 21 G2P1L0 bleeding anaemia 3MA 12 CM N 2,76,739 11 CM    -    - SE ND 6 mon IOG
46 245/10 22 G2P1L1 bleeding anaemia 4MA 20 CM,B/L TLC N 4,61,314 16 CM   -   - SE ND 4 mon IOG
47 247/10 28 G3A2 Spotting Repeatmole,HIV+ve 2MA 10 PM N 196042 8 PM   -   - SE ND 6  mon IOG
48 252/10 23 G2A1 bleeding   -  2MA 10 CM N 136164 9 CM    -    - SE ND 6 mon IOG
49 259/10 42 G3 P2L2 USG vomiting ,RHD 3MA 12 CM N 271504 32 CM   -  - SE Nd 2 mon IOG
50 261/10 22 G2P1L1 spotting    - 2MA 12 CM N 4,16,581 40 CM GTN 1 SE/ MTX4/      Act3 ND 1 mon IOG
51 262/10 30 G2P1L1 spotting vomiting 2MA 18 CM N 5,00,000 16 CM   -   - SE ND 6 mon IOG
52 270/10 21 G2P1L1 USG   - 2MA 10 CM N 312214 8 CM   -   - SE ND 9 mon IOG
53 274/10 21 primi USG    - 3MA 10 CM N 60189    -  CM   -   - SE  Defaulter IOG
54 276/10 19 Primi USG    - 2MA 12 CM N 56129  -  CM   -   - SE Defaulter IOG
55 277/10 20 G2P1L1 bleeding anemia 3MA 16 CM N 100445 16 CM     -    - SE ND 6 mon IOG
56 278/10 21 G3P2L2 bleeding   - 2MA 24 CM N 113194 35 CM GTN 0 SE/MTX 7 ND 1 mon IOG
57 280/10 26 G3P1L1A1 USG   - 5MA 20
CM,doppler- invasive
mole N 40,200 18 CM GTN 1 SE/MTX4 ND 8 mon IOG
58 283/10 29 G3P1L1A1 bleeding    - 4MA 20 CM N 27795 8 CM   -  - SE ND 7 mon IOG
59 287/10 20 G2A1 USG anemia 2MA 10 CM N 12,451 17 CM GTN 1
SE/ MTX 5
/EMACO3 ND 6 mon pvt
60 289/10 20 G3A2 USG anemia 5MA 20 CM N 17,979   - CM   -   - SE Defaulter IOG
61 290/10 25 primi USG    - 4MA 20 CM N 367356 19 CM GTN 0 SE/MTX 6 ND 5 mon IOG
62 291/10 35 G2P1L0 USG    - 3MA 12 PM N 34692 16 PM   -   - SE ND 5 mon IOG
63 297/10 26 G2P1L1 USG    - 4MA 12 CM,B/L TLC N 457360   - CM   -    - SE Defaulter IOG
64 298/10 23 primi USG    - 3MA 12 PM N 89,151 14 PM    -   - SE ND 5 mon IOG
65 299/10 25 primi USG    - 5MA 16 CM N 12,253 10 CM   -   - SE ND 5 mon IOG
66 300/10 22 G4P2L1A1 spotting   - 4MA 24 CM N 5,00,000     - CM   -    - SE Defaulter IOG
67 301/10 26 G4P1L1A1 bleeding   - 2MA 10 CM N 2,17,681 19 CM GTN 2 SE/ MTX 8 ND 6 mon pvt
68 136/01 21 G4A3 USG repeat mole 5MA 20
CM,Invasive mole,B/L
TLC N 5,00,000   - CM GTN 3 SE/MTX 3 on treatment IOG
69 o1/11 20 primi USG    - 2MA 12 PM N 2560 12 PM   -   - SE ND 4 mon IOG
70 o2/11 20 G2A1 USG bicornuate uterus 2MA 12
CMin left horn of
bicornuate uterus N 1850 9 CM   -   - SE ND 4 mon IOG
71 o4/11 30 G4P1L1A2 USG    - 3MA 12 CM N 2,40,898 25   CM   -   - SE ND 4 mon IOG
72 o5/11 20 G2A1 USG anemia 2 MA 12 CM N 36,947 9 CM   -  - SE ND 4 mon IOG
73 o6/11 22 primi USG   - 2MA 10 PM N 18628 8 PM   -   - SE ND 5 mon IOG
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74 o7/11 22 G3P1L1A1 USG repeat mole 2MA 16 CM,B/L TLC N 2,00,000 22 CM GTN 2
SE/MTX2/
EMACO 5 ND 3 mon pvt
75 o8/11 26 primi spotting  vomiting 3MA 20 CM N 5,00,000 14 CM   -   - SE ND 2 mon IOG
76 o9/11 25 G3 P2L2 bleeding     - 3MA 16 CM N 2408 8 CM   -   - SE ND 2  mon IOG
77 10/,11 20 G2P1L1 USG vomiting 2MA 20 CM N 1,50,000    - CM   -   - SE Defaulter IOG
78 12/,11 19 G3P1L1A1 USG rpt SE 2MA 12 CM,B/L TLC N 12,440 - CM   GTN 0 SE/MTX5 defaulter(april) pvt
79 14/11 20 G2P1L0 USG RHD 2MA 10 PM N 9260 8 PM  -   - SE ND 5 mon IOG
80 19/11 25 G2P1L1 bleeding vomiting 3MA 12 CM N 36,566 8 CM   -   - SE ND 4 mon IOG
81 20/11 25 G2P1L1 USG USG prominent vascularity 3MA 20 Invasive mole N 5,00,000 25 CM GTN 2 SE/EMACO5 ND 4 mon IOG
82 23/11 23 primi spotting vomiting ,HbsAg +ve 3MA 12 PM N 3,920 12 PM  -   - SE ND 5 mon IOG
83 31/11 25 primi USG   - 2MA 10 CM N 2,77,871 9 CM   -   - SE ND 4 mon IOG
84 33/11 22 G2P1L1 USG vomiting 3MA 16 CM ,B/L TLC N 49,272 12 CM   -   - SE ND 4 mon IOG
85 38/11 22 G3P1L1A1 USG   - 3MA 18 CM N 4,00,000 9 CM   -   - SE ND 3 mon IOG
86 39/11 22 G2P1L1 USG   - 2MA 10 CM N 5,00,000 16 CM   -   - SE ND 1 mon IOG
87 40/11 26 G2P1L1 spotting anemia 3MA 16 CM N 4,25,125 9 CM   -   - SE ND 3 mon IOG
88 41/11 21 primi USG   - 3MA 12 PM N 7750 18 PM GTN 0
SE/MTX3/
EMACO4 ND 4 mon Pvt
89 44/11 20 G2P1L1 USG   - 4MA 20 CM N 3,49,235 16 CM   -   - SE ND 3 mon IOG
90 45/11 20 primi USG   - 2MA 10 CM N 3943 10 CM   -   -  SE ND 4 mon IOG
91 50/11 23 primi USG   - 2MA 10 CM N 116712 10 CM   -   - SE ND 4 mon IOG
92 62/11 20 primi USG   - 2MA 10 CM N 2,08,820 10 CM   -   - SE ND 2 mon IOG
93 63/11 28 G3P1L1A1 USG   - 3MA 12 CM N 319,281 12 CM   -   - SE ND 4 mon IOG
94 64/11 24 G3P2L1 spotting   - 4MA 12 PM N 18,724 8 PM   -   - SE ND 3 mon IOG
95 66/11 26 G3 P2L2 bleeding vomiting 4MA 12 CM N 91,131 8 CM   -   - SE ND 4 mon IOG
96 70/11 29 G2P1L1 bleeding   - 4MA 18 CM N 24,176 13 CM   -   - SE ND 3 mon IOG
97 71/11 32 G2P1L1 bleeding   - 2MA 10 PM N 3,833 9 PM  -   - SE ND 4 mon IOG
98 75/11 19 primi USG   - 2MA 10 CM N 5,000 8 CM  -   - SE ND 1 mon IOG
99 76/11 26 G3P2L1 spotting  - 3MA 12 PM N 14,899 14 PM   -  - SE ND 3 mon iOG
100 77/11 22 G3P2L1 Bleeding   - 2MA 10 CM N 2,612 10 CM   -   - SE ND 3 mon IOG
101 78/11 20 primi USG   - 4MA 16 CM N 2,70,714 12 CM   -   - SE ND 2 mon IOG
102 79/11 26 G4P1L1A2 bleeding vomiting 4MA 10 PM N 1,68,532 8 PM   -   - Se ND 2 mon IOG
103 86/11 27 G2P1L1 spotting vomiting 5MA 16 CM N 73,444 9 CM   -   - SE ND 2 mon IOG
104 87/11 18 primi USG    - 3MA 20 CM N 10,003 9 CM   -   -  SE ND 3 mon IOG
105 89/11 22 G3P2L2 spotting   - 5MA 18 CM N 7,654 8 CM   -    - SE ND 2 mon IOG
106 90/11 27 G2P1L1 USG   - 3MA 16 CM N 7,143 8 CM   -   - SE ND 3 mon IOG
107 91/11 28 primi USG vomiting 4MA 10 CM N 1,87,722 8 CM   -  - SE ND 2 mon IOG
108 94/11 20 primi USG   - 4MA 16 CM N 4,57,439 12 CM   -  - SE ND 1 mon IOG
109 98/11 24 G3P2L1 spotting    -- 3MA 12 CM N 5,00,000 10 CM    -   - SE ND 1 mon IOG
110 101/11 23 G2P1L1 bleeding    - 4MA 20 CM N 2,25,000  - CM   -   - SE defaulter IOG
111 102/11 23 primi USG   - 3MA 16 PM N 6,579 12 PM   -   - SE ND 3 mon IOG
112 103/11 30 G6P4L4A1 spotting   - 3MA 12 CM N 9,065 8 CM  -   - SE ND 3 mon IOG
113 104/11 23 primi USG   - 3MA 12 CM N 1,12,000 10 CM   -   - SE ND 2 mon IOG
114 159/10 26 G3P1L1A1 bleeding rpt SE 5MA 20 CM N 7912 21 GTN GTN 1 SE/MTX9 ND 10 mon KMC
KEY TO MASTER CHART
G3P1L1A1 - Gravida 1, Para 1, Live birth 1, Abortion 1
FTND – full term normal delivery
FTLSCS – full term lower segment caesarean section
USG – Ultrasound
DCDA - Dichorionic Diamniotic
AION - Anterior ischemic optic neuropathy
SE  - Suction Evacuation
Rpt  -   Repeat
LCB - last child birth
PIH - pregnancy induced hypertension
POC  - Products of conception
RHD  - Rheumatic heart disease
BA - Bronchial asthma
 HIV - Human immunodeficiency virus
HbSAg - Hepatitis B surface Antigen positive
MA - months of amenorrhea
CM - Complete mole
PM - Partial mole
B/L - bilateral
TLC - Theca leutin cysts
Ut -  uterus
N - Normal
Mets - metastasis
TAH - Total abdominal hysterectomy
hcg - human chorionic gonadotrophin
GTN - Gestational trophoblastic neoplasia
LN - Labour Natural
Act2 - Actinomycin 2 cycles
Mtx 7 - Methotrexate 7 cycles
EMA- CO – Etoposide, Methotrexate, Actinomycin,
Cyclophosphamide, Oncovin
PEB  - Cisplatin , Etoposide, bleomycin
RT - Radiotherapy
TAT - Transabdominal tubectomy
ND 2mon - Not detectable for 2 months
IOG - Institute of obstetrics and Gynecology
Pvt - private hospital
KGH  - Kasturba Gandhi hospital
KMC - Kilpauk Medical College
SMC - Stanley medical College
GH - Government hospital
